id	sid	tid	token	lemma	pos
cord-312340-hpuoren5	1	1	key	key	NN
cord-312340-hpuoren5	1	2	:	:	:
cord-312340-hpuoren5	1	3	cord-312340-hpuoren5	cord-312340-hpuoren5	NNP
cord-312340-hpuoren5	1	4	authors	author	NNS
cord-312340-hpuoren5	1	5	:	:	:
cord-312340-hpuoren5	1	6	Holstein	Holstein	NNP
cord-312340-hpuoren5	1	7	,	,	,
cord-312340-hpuoren5	1	8	Sarah	Sarah	NNP
cord-312340-hpuoren5	1	9	A.	A.	NNP
cord-312340-hpuoren5	1	10	;	;	:
cord-312340-hpuoren5	1	11	Vose	Vose	NNP
cord-312340-hpuoren5	1	12	,	,	,
cord-312340-hpuoren5	1	13	Julie	Julie	NNP
cord-312340-hpuoren5	1	14	M.	M.	NNP
cord-312340-hpuoren5	1	15	title	title	NN
cord-312340-hpuoren5	1	16	:	:	:
cord-312340-hpuoren5	1	17	Oncology	Oncology	NNP
cord-312340-hpuoren5	1	18	Treatment	Treatment	NNP
cord-312340-hpuoren5	1	19	in	in	IN
cord-312340-hpuoren5	1	20	the	the	DT
cord-312340-hpuoren5	1	21	Era	era	NN
cord-312340-hpuoren5	1	22	of	of	IN
cord-312340-hpuoren5	1	23	COVID‐19	covid‐19	NN
cord-312340-hpuoren5	2	1	:	:	:
cord-312340-hpuoren5	2	2	We	-PRON-	PRP
cord-312340-hpuoren5	2	3	Can	can	MD
cord-312340-hpuoren5	2	4	not	not	RB
cord-312340-hpuoren5	2	5	Afford	afford	VB
cord-312340-hpuoren5	2	6	to	to	TO
cord-312340-hpuoren5	2	7	Hit	hit	VB
cord-312340-hpuoren5	2	8	the	the	DT
cord-312340-hpuoren5	2	9	Pause	pause	NN
cord-312340-hpuoren5	2	10	Button	Button	NNP
cord-312340-hpuoren5	2	11	date	date	NN
cord-312340-hpuoren5	3	1	:	:	:
cord-312340-hpuoren5	3	2	2020	2020	CD
cord-312340-hpuoren5	3	3	-	-	HYPH
cord-312340-hpuoren5	3	4	06	06	CD
cord-312340-hpuoren5	3	5	-	-	SYM
cord-312340-hpuoren5	3	6	02	02	CD
cord-312340-hpuoren5	3	7	journal	journal	NN
cord-312340-hpuoren5	3	8	:	:	:
cord-312340-hpuoren5	4	1	Clin	Clin	NNP
cord-312340-hpuoren5	4	2	Pharmacol	Pharmacol	NNP
cord-312340-hpuoren5	4	3	Ther	Ther	NNP
cord-312340-hpuoren5	4	4	DOI	doi	NN
cord-312340-hpuoren5	4	5	:	:	:
cord-312340-hpuoren5	4	6	10.1002	10.1002	CD
cord-312340-hpuoren5	4	7	/	/	SYM
cord-312340-hpuoren5	4	8	cpt.1920	cpt.1920	NN
cord-312340-hpuoren5	4	9	sha	sha	NNP
cord-312340-hpuoren5	4	10	:	:	:
cord-312340-hpuoren5	4	11	7c88357935cb331b64bfdd7511a600edb6f92a57	7c88357935cb331b64bfdd7511a600edb6f92a57	CD
cord-312340-hpuoren5	4	12	doc_id	doc_id	CD
cord-312340-hpuoren5	4	13	:	:	:
cord-312340-hpuoren5	4	14	312340	312340	CD
cord-312340-hpuoren5	4	15	cord_uid	cord_uid	NNS
cord-312340-hpuoren5	4	16	:	:	:
cord-312340-hpuoren5	4	17	hpuoren5	hpuoren5	NNP
cord-312340-hpuoren5	5	1	The	the	DT
cord-312340-hpuoren5	5	2	COVID‐19	COVID‐19	NNP
cord-312340-hpuoren5	5	3	pandemic	pandemic	NN
cord-312340-hpuoren5	5	4	has	have	VBZ
cord-312340-hpuoren5	5	5	far‐reaching	far‐reache	VBG
cord-312340-hpuoren5	5	6	ramifications	ramification	NNS
cord-312340-hpuoren5	5	7	for	for	IN
cord-312340-hpuoren5	5	8	patients	patient	NNS
cord-312340-hpuoren5	5	9	undergoing	undergo	VBG
cord-312340-hpuoren5	5	10	cancer	cancer	NN
cord-312340-hpuoren5	5	11	treatment	treatment	NN
cord-312340-hpuoren5	5	12	.	.	.
cord-312340-hpuoren5	6	1	Oncologists	oncologist	NNS
cord-312340-hpuoren5	6	2	and	and	CC
cord-312340-hpuoren5	6	3	institutions	institution	NNS
cord-312340-hpuoren5	6	4	have	have	VBP
cord-312340-hpuoren5	6	5	adjusted	adjust	VBN
cord-312340-hpuoren5	6	6	treatment	treatment	NN
cord-312340-hpuoren5	6	7	practices	practice	NNS
cord-312340-hpuoren5	6	8	and	and	CC
cord-312340-hpuoren5	6	9	,	,	,
cord-312340-hpuoren5	6	10	in	in	IN
cord-312340-hpuoren5	6	11	many	many	JJ
cord-312340-hpuoren5	6	12	cases	case	NNS
cord-312340-hpuoren5	6	13	,	,	,
cord-312340-hpuoren5	6	14	significantly	significantly	RB
cord-312340-hpuoren5	6	15	curtailed	curtail	VBD
cord-312340-hpuoren5	6	16	clinical	clinical	JJ
cord-312340-hpuoren5	6	17	trial	trial	NN
cord-312340-hpuoren5	6	18	conduct	conduct	NN
cord-312340-hpuoren5	6	19	.	.	.
cord-312340-hpuoren5	7	1	Whether	whether	IN
cord-312340-hpuoren5	7	2	these	these	DT
cord-312340-hpuoren5	7	3	adjustments	adjustment	NNS
cord-312340-hpuoren5	7	4	mitigate	mitigate	VBP
cord-312340-hpuoren5	7	5	the	the	DT
cord-312340-hpuoren5	7	6	risk	risk	NN
cord-312340-hpuoren5	7	7	of	of	IN
cord-312340-hpuoren5	7	8	COVID‐19	covid‐19	JJ
cord-312340-hpuoren5	7	9	complications	complication	NNS
cord-312340-hpuoren5	7	10	without	without	IN
cord-312340-hpuoren5	7	11	jeopardizing	jeopardize	VBG
cord-312340-hpuoren5	7	12	treatment	treatment	NN
cord-312340-hpuoren5	7	13	of	of	IN
cord-312340-hpuoren5	7	14	the	the	DT
cord-312340-hpuoren5	7	15	cancer	cancer	NN
cord-312340-hpuoren5	7	16	is	be	VBZ
cord-312340-hpuoren5	7	17	unknown	unknown	JJ
cord-312340-hpuoren5	7	18	.	.	.
cord-312340-hpuoren5	8	1	Given	give	VBN
cord-312340-hpuoren5	8	2	the	the	DT
cord-312340-hpuoren5	8	3	expected	expect	VBN
cord-312340-hpuoren5	8	4	duration	duration	NN
cord-312340-hpuoren5	8	5	of	of	IN
cord-312340-hpuoren5	8	6	the	the	DT
cord-312340-hpuoren5	8	7	pandemic	pandemic	NN
cord-312340-hpuoren5	8	8	,	,	,
cord-312340-hpuoren5	8	9	it	-PRON-	PRP
cord-312340-hpuoren5	8	10	is	be	VBZ
cord-312340-hpuoren5	8	11	imperative	imperative	JJ
cord-312340-hpuoren5	8	12	that	that	DT
cord-312340-hpuoren5	8	13	treatment	treatment	NN
cord-312340-hpuoren5	8	14	of	of	IN
cord-312340-hpuoren5	8	15	the	the	DT
cord-312340-hpuoren5	8	16	patient	patient	NN
cord-312340-hpuoren5	8	17	's	's	POS
cord-312340-hpuoren5	8	18	cancer	cancer	NN
cord-312340-hpuoren5	8	19	remain	remain	VBP
cord-312340-hpuoren5	8	20	the	the	DT
cord-312340-hpuoren5	8	21	priority	priority	NN
cord-312340-hpuoren5	8	22	and	and	CC
cord-312340-hpuoren5	8	23	that	that	IN
cord-312340-hpuoren5	8	24	advances	advance	VBZ
cord-312340-hpuoren5	8	25	in	in	IN
cord-312340-hpuoren5	8	26	drug	drug	NN
cord-312340-hpuoren5	8	27	development	development	NN
cord-312340-hpuoren5	8	28	continue	continue	VBP
cord-312340-hpuoren5	8	29	through	through	IN
cord-312340-hpuoren5	8	30	appropriately	appropriately	RB
cord-312340-hpuoren5	8	31	designed	design	VBN
cord-312340-hpuoren5	8	32	clinical	clinical	JJ
cord-312340-hpuoren5	8	33	trials	trial	NNS
cord-312340-hpuoren5	8	34	.	.	.
cord-312340-hpuoren5	9	1	The	the	DT
cord-312340-hpuoren5	9	2	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	9	3	pandemic	pandemic	NN
cord-312340-hpuoren5	9	4	has	have	VBZ
cord-312340-hpuoren5	9	5	far	far	RB
cord-312340-hpuoren5	9	6	-	-	HYPH
cord-312340-hpuoren5	9	7	reaching	reach	VBG
cord-312340-hpuoren5	9	8	ramifications	ramification	NNS
cord-312340-hpuoren5	9	9	for	for	IN
cord-312340-hpuoren5	9	10	patients	patient	NNS
cord-312340-hpuoren5	9	11	undergoing	undergo	VBG
cord-312340-hpuoren5	9	12	cancer	cancer	NN
cord-312340-hpuoren5	9	13	treatment	treatment	NN
cord-312340-hpuoren5	9	14	.	.	.
cord-312340-hpuoren5	10	1	Oncologists	oncologist	NNS
cord-312340-hpuoren5	10	2	and	and	CC
cord-312340-hpuoren5	10	3	institutions	institution	NNS
cord-312340-hpuoren5	10	4	have	have	VBP
cord-312340-hpuoren5	10	5	adjusted	adjust	VBN
cord-312340-hpuoren5	10	6	treatment	treatment	NN
cord-312340-hpuoren5	10	7	practices	practice	NNS
cord-312340-hpuoren5	10	8	and	and	CC
cord-312340-hpuoren5	10	9	,	,	,
cord-312340-hpuoren5	10	10	in	in	IN
cord-312340-hpuoren5	10	11	many	many	JJ
cord-312340-hpuoren5	10	12	cases	case	NNS
cord-312340-hpuoren5	10	13	,	,	,
cord-312340-hpuoren5	10	14	significantly	significantly	RB
cord-312340-hpuoren5	10	15	curtailed	curtail	VBD
cord-312340-hpuoren5	10	16	clinical	clinical	JJ
cord-312340-hpuoren5	10	17	trial	trial	NN
cord-312340-hpuoren5	10	18	conduct	conduct	NN
cord-312340-hpuoren5	10	19	.	.	.
cord-312340-hpuoren5	11	1	Whether	whether	IN
cord-312340-hpuoren5	11	2	these	these	DT
cord-312340-hpuoren5	11	3	adjustments	adjustment	NNS
cord-312340-hpuoren5	11	4	mitigate	mitigate	VBP
cord-312340-hpuoren5	11	5	the	the	DT
cord-312340-hpuoren5	11	6	risk	risk	NN
cord-312340-hpuoren5	11	7	of	of	IN
cord-312340-hpuoren5	11	8	COVID-19	covid-19	JJ
cord-312340-hpuoren5	11	9	complications	complication	NNS
cord-312340-hpuoren5	11	10	without	without	IN
cord-312340-hpuoren5	11	11	jeopardizing	jeopardize	VBG
cord-312340-hpuoren5	11	12	treatment	treatment	NN
cord-312340-hpuoren5	11	13	of	of	IN
cord-312340-hpuoren5	11	14	the	the	DT
cord-312340-hpuoren5	11	15	cancer	cancer	NN
cord-312340-hpuoren5	11	16	is	be	VBZ
cord-312340-hpuoren5	11	17	unknown	unknown	JJ
cord-312340-hpuoren5	11	18	.	.	.
cord-312340-hpuoren5	12	1	Given	give	VBN
cord-312340-hpuoren5	12	2	the	the	DT
cord-312340-hpuoren5	12	3	expected	expect	VBN
cord-312340-hpuoren5	12	4	duration	duration	NN
cord-312340-hpuoren5	12	5	of	of	IN
cord-312340-hpuoren5	12	6	the	the	DT
cord-312340-hpuoren5	12	7	pandemic	pandemic	NN
cord-312340-hpuoren5	12	8	,	,	,
cord-312340-hpuoren5	12	9	it	-PRON-	PRP
cord-312340-hpuoren5	12	10	is	be	VBZ
cord-312340-hpuoren5	12	11	imperative	imperative	JJ
cord-312340-hpuoren5	12	12	that	that	DT
cord-312340-hpuoren5	12	13	treatment	treatment	NN
cord-312340-hpuoren5	12	14	of	of	IN
cord-312340-hpuoren5	12	15	the	the	DT
cord-312340-hpuoren5	12	16	patient	patient	NN
cord-312340-hpuoren5	12	17	's	's	POS
cord-312340-hpuoren5	12	18	cancer	cancer	NN
cord-312340-hpuoren5	12	19	remain	remain	VBP
cord-312340-hpuoren5	12	20	the	the	DT
cord-312340-hpuoren5	12	21	priority	priority	NN
cord-312340-hpuoren5	12	22	and	and	CC
cord-312340-hpuoren5	12	23	that	that	IN
cord-312340-hpuoren5	12	24	advances	advance	VBZ
cord-312340-hpuoren5	12	25	in	in	IN
cord-312340-hpuoren5	12	26	drug	drug	NN
cord-312340-hpuoren5	12	27	development	development	NN
cord-312340-hpuoren5	12	28	continue	continue	VBP
cord-312340-hpuoren5	12	29	through	through	IN
cord-312340-hpuoren5	12	30	appropriately	appropriately	RB
cord-312340-hpuoren5	12	31	designed	design	VBN
cord-312340-hpuoren5	12	32	clinical	clinical	JJ
cord-312340-hpuoren5	12	33	trials	trial	NNS
cord-312340-hpuoren5	12	34	.	.	.
cord-312340-hpuoren5	13	1	This	this	DT
cord-312340-hpuoren5	13	2	article	article	NN
cord-312340-hpuoren5	13	3	is	be	VBZ
cord-312340-hpuoren5	13	4	protected	protect	VBN
cord-312340-hpuoren5	13	5	by	by	IN
cord-312340-hpuoren5	13	6	copyright	copyright	NN
cord-312340-hpuoren5	13	7	.	.	.
cord-312340-hpuoren5	14	1	All	all	DT
cord-312340-hpuoren5	14	2	rights	right	NNS
cord-312340-hpuoren5	14	3	reserved	reserve	VBN
cord-312340-hpuoren5	14	4	Perspective	perspective	NN
cord-312340-hpuoren5	14	5	:	:	:
cord-312340-hpuoren5	14	6	The	the	DT
cord-312340-hpuoren5	14	7	scope	scope	NN
cord-312340-hpuoren5	14	8	of	of	IN
cord-312340-hpuoren5	14	9	the	the	DT
cord-312340-hpuoren5	14	10	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	14	11	pandemic	pandemic	NN
cord-312340-hpuoren5	14	12	is	be	VBZ
cord-312340-hpuoren5	14	13	unprecedented	unprecedented	JJ
cord-312340-hpuoren5	14	14	in	in	IN
cord-312340-hpuoren5	14	15	modern	modern	JJ
cord-312340-hpuoren5	14	16	history	history	NN
cord-312340-hpuoren5	14	17	.	.	.
cord-312340-hpuoren5	15	1	Any	any	DT
cord-312340-hpuoren5	15	2	citation	citation	NN
cord-312340-hpuoren5	15	3	of	of	IN
cord-312340-hpuoren5	15	4	infection	infection	NN
cord-312340-hpuoren5	15	5	/	/	SYM
cord-312340-hpuoren5	15	6	mortality	mortality	NN
cord-312340-hpuoren5	15	7	statistics	statistic	NNS
cord-312340-hpuoren5	15	8	is	be	VBZ
cord-312340-hpuoren5	15	9	immediately	immediately	RB
cord-312340-hpuoren5	15	10	outdated	outdate	VBN
cord-312340-hpuoren5	15	11	,	,	,
cord-312340-hpuoren5	15	12	but	but	CC
cord-312340-hpuoren5	15	13	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	15	14	has	have	VBZ
cord-312340-hpuoren5	15	15	become	become	VBN
cord-312340-hpuoren5	15	16	the	the	DT
cord-312340-hpuoren5	15	17	number	number	NN
cord-312340-hpuoren5	15	18	one	one	CD
cord-312340-hpuoren5	15	19	cause	cause	NN
cord-312340-hpuoren5	15	20	of	of	IN
cord-312340-hpuoren5	15	21	death	death	NN
cord-312340-hpuoren5	15	22	in	in	IN
cord-312340-hpuoren5	15	23	the	the	DT
cord-312340-hpuoren5	15	24	United	United	NNP
cord-312340-hpuoren5	15	25	States	States	NNP
cord-312340-hpuoren5	15	26	(	(	-LRB-
cord-312340-hpuoren5	15	27	US	US	NNP
cord-312340-hpuoren5	15	28	)	)	-RRB-
cord-312340-hpuoren5	15	29	.	.	.
cord-312340-hpuoren5	16	1	It	-PRON-	PRP
cord-312340-hpuoren5	16	2	is	be	VBZ
cord-312340-hpuoren5	16	3	increasingly	increasingly	RB
cord-312340-hpuoren5	16	4	recognized	recognize	VBN
cord-312340-hpuoren5	16	5	that	that	IN
cord-312340-hpuoren5	16	6	older	old	JJR
cord-312340-hpuoren5	16	7	individuals	individual	NNS
cord-312340-hpuoren5	16	8	and	and	CC
cord-312340-hpuoren5	16	9	those	those	DT
cord-312340-hpuoren5	16	10	with	with	IN
cord-312340-hpuoren5	16	11	comorbidities	comorbiditie	NNS
cord-312340-hpuoren5	16	12	are	be	VBP
cord-312340-hpuoren5	16	13	at	at	IN
cord-312340-hpuoren5	16	14	higher	high	JJR
cord-312340-hpuoren5	16	15	risk	risk	NN
cord-312340-hpuoren5	16	16	for	for	IN
cord-312340-hpuoren5	16	17	mortality	mortality	NN
cord-312340-hpuoren5	16	18	,	,	,
cord-312340-hpuoren5	16	19	including	include	VBG
cord-312340-hpuoren5	16	20	those	those	DT
cord-312340-hpuoren5	16	21	with	with	IN
cord-312340-hpuoren5	16	22	active	active	JJ
cord-312340-hpuoren5	16	23	malignancies	malignancy	NNS
cord-312340-hpuoren5	16	24	.	.	.
cord-312340-hpuoren5	17	1	In	in	IN
cord-312340-hpuoren5	17	2	the	the	DT
cord-312340-hpuoren5	17	3	US	US	NNP
cord-312340-hpuoren5	17	4	,	,	,
cord-312340-hpuoren5	17	5	the	the	DT
cord-312340-hpuoren5	17	6	median	median	JJ
cord-312340-hpuoren5	17	7	age	age	NN
cord-312340-hpuoren5	17	8	of	of	IN
cord-312340-hpuoren5	17	9	cancer	cancer	NN
cord-312340-hpuoren5	17	10	diagnosis	diagnosis	NN
cord-312340-hpuoren5	17	11	is	be	VBZ
cord-312340-hpuoren5	17	12	66	66	CD
cord-312340-hpuoren5	17	13	years	year	NNS
cord-312340-hpuoren5	17	14	(	(	-LRB-
cord-312340-hpuoren5	17	15	NCI	NCI	NNP
cord-312340-hpuoren5	17	16	SEER	SEER	NNP
cord-312340-hpuoren5	17	17	data	datum	NNS
cord-312340-hpuoren5	17	18	)	)	-RRB-
cord-312340-hpuoren5	17	19	and	and	CC
cord-312340-hpuoren5	17	20	,	,	,
cord-312340-hpuoren5	17	21	until	until	IN
cord-312340-hpuoren5	17	22	the	the	DT
cord-312340-hpuoren5	17	23	advent	advent	NN
cord-312340-hpuoren5	17	24	of	of	IN
cord-312340-hpuoren5	17	25	SARS	SARS	NNP
cord-312340-hpuoren5	17	26	-	-	HYPH
cord-312340-hpuoren5	17	27	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	17	28	,	,	,
cord-312340-hpuoren5	17	29	cancer	cancer	NN
cord-312340-hpuoren5	17	30	was	be	VBD
cord-312340-hpuoren5	17	31	the	the	DT
cord-312340-hpuoren5	17	32	second	second	JJ
cord-312340-hpuoren5	17	33	leading	leading	JJ
cord-312340-hpuoren5	17	34	cause	cause	NN
cord-312340-hpuoren5	17	35	of	of	IN
cord-312340-hpuoren5	17	36	death	death	NN
cord-312340-hpuoren5	17	37	.	.	.
cord-312340-hpuoren5	18	1	Cancer	cancer	NN
cord-312340-hpuoren5	18	2	therapies	therapy	NNS
cord-312340-hpuoren5	18	3	include	include	VBP
cord-312340-hpuoren5	18	4	cytotoxic	cytotoxic	JJ
cord-312340-hpuoren5	18	5	agents	agent	NNS
cord-312340-hpuoren5	18	6	and/or	and/or	CC
cord-312340-hpuoren5	18	7	targeted	targeted	JJ
cord-312340-hpuoren5	18	8	agents	agent	NNS
cord-312340-hpuoren5	18	9	and/or	and/or	CC
cord-312340-hpuoren5	18	10	immune	immune	JJ
cord-312340-hpuoren5	18	11	modifying	modify	VBG
cord-312340-hpuoren5	18	12	agents	agent	NNS
cord-312340-hpuoren5	18	13	,	,	,
cord-312340-hpuoren5	18	14	all	all	DT
cord-312340-hpuoren5	18	15	of	of	IN
cord-312340-hpuoren5	18	16	which	which	WDT
cord-312340-hpuoren5	18	17	have	have	VBP
cord-312340-hpuoren5	18	18	the	the	DT
cord-312340-hpuoren5	18	19	potential	potential	NN
cord-312340-hpuoren5	18	20	to	to	TO
cord-312340-hpuoren5	18	21	alter	alter	VB
cord-312340-hpuoren5	18	22	the	the	DT
cord-312340-hpuoren5	18	23	immune	immune	JJ
cord-312340-hpuoren5	18	24	response	response	NN
cord-312340-hpuoren5	18	25	to	to	IN
cord-312340-hpuoren5	18	26	infectious	infectious	JJ
cord-312340-hpuoren5	18	27	pathogens	pathogen	NNS
cord-312340-hpuoren5	18	28	.	.	.
cord-312340-hpuoren5	19	1	Many	many	JJ
cord-312340-hpuoren5	19	2	hematological	hematological	JJ
cord-312340-hpuoren5	19	3	malignancies	malignancy	NNS
cord-312340-hpuoren5	19	4	utilize	utilize	VBP
cord-312340-hpuoren5	19	5	autologous	autologous	JJ
cord-312340-hpuoren5	19	6	or	or	CC
cord-312340-hpuoren5	19	7	allogeneic	allogeneic	IN
cord-312340-hpuoren5	19	8	stem	stem	NN
cord-312340-hpuoren5	19	9	cell	cell	NN
cord-312340-hpuoren5	19	10	transplantation	transplantation	NN
cord-312340-hpuoren5	19	11	(	(	-LRB-
cord-312340-hpuoren5	19	12	SCT	SCT	NNP
cord-312340-hpuoren5	19	13	)	)	-RRB-
cord-312340-hpuoren5	19	14	or	or	CC
cord-312340-hpuoren5	19	15	cellular	cellular	JJ
cord-312340-hpuoren5	19	16	therapies	therapy	NNS
cord-312340-hpuoren5	19	17	(	(	-LRB-
cord-312340-hpuoren5	19	18	e.g.	e.g.	RB
cord-312340-hpuoren5	19	19	,	,	,
cord-312340-hpuoren5	19	20	chimeric	chimeric	JJ
cord-312340-hpuoren5	19	21	antigen	antigen	NN
cord-312340-hpuoren5	19	22	receptor	receptor	NN
cord-312340-hpuoren5	19	23	(	(	-LRB-
cord-312340-hpuoren5	19	24	CAR	car	NN
cord-312340-hpuoren5	19	25	)	)	-RRB-
cord-312340-hpuoren5	19	26	T	t	NN
cord-312340-hpuoren5	19	27	-	-	HYPH
cord-312340-hpuoren5	19	28	cell	cell	NN
cord-312340-hpuoren5	19	29	therapy	therapy	NN
cord-312340-hpuoren5	19	30	)	)	-RRB-
cord-312340-hpuoren5	19	31	,	,	,
cord-312340-hpuoren5	19	32	all	all	DT
cord-312340-hpuoren5	19	33	of	of	IN
cord-312340-hpuoren5	19	34	which	which	WDT
cord-312340-hpuoren5	19	35	have	have	VBP
cord-312340-hpuoren5	19	36	profound	profound	JJ
cord-312340-hpuoren5	19	37	impacts	impact	NNS
cord-312340-hpuoren5	19	38	on	on	IN
cord-312340-hpuoren5	19	39	the	the	DT
cord-312340-hpuoren5	19	40	immune	immune	JJ
cord-312340-hpuoren5	19	41	system	system	NN
cord-312340-hpuoren5	19	42	.	.	.
cord-312340-hpuoren5	20	1	Emerging	emerge	VBG
cord-312340-hpuoren5	20	2	data	datum	NNS
cord-312340-hpuoren5	20	3	from	from	IN
cord-312340-hpuoren5	20	4	China	China	NNP
cord-312340-hpuoren5	20	5	and	and	CC
cord-312340-hpuoren5	20	6	the	the	DT
cord-312340-hpuoren5	20	7	US	US	NNP
cord-312340-hpuoren5	20	8	highlight	highlight	VB
cord-312340-hpuoren5	20	9	the	the	DT
cord-312340-hpuoren5	20	10	increased	increase	VBN
cord-312340-hpuoren5	20	11	risk	risk	NN
cord-312340-hpuoren5	20	12	of	of	IN
cord-312340-hpuoren5	20	13	oncology	oncology	NN
cord-312340-hpuoren5	20	14	patients	patient	NNS
cord-312340-hpuoren5	20	15	for	for	IN
cord-312340-hpuoren5	20	16	morbidity	morbidity	NN
cord-312340-hpuoren5	20	17	and	and	CC
cord-312340-hpuoren5	20	18	mortality	mortality	NN
cord-312340-hpuoren5	20	19	from	from	IN
cord-312340-hpuoren5	20	20	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	20	21	.	.	.
cord-312340-hpuoren5	21	1	A	a	DT
cord-312340-hpuoren5	21	2	report	report	NN
cord-312340-hpuoren5	21	3	from	from	IN
cord-312340-hpuoren5	21	4	China	China	NNP
cord-312340-hpuoren5	21	5	described	describe	VBD
cord-312340-hpuoren5	21	6	the	the	DT
cord-312340-hpuoren5	21	7	outcomes	outcome	NNS
cord-312340-hpuoren5	21	8	of	of	IN
cord-312340-hpuoren5	21	9	1524	1524	CD
cord-312340-hpuoren5	21	10	patients	patient	NNS
cord-312340-hpuoren5	21	11	with	with	IN
cord-312340-hpuoren5	21	12	solid	solid	JJ
cord-312340-hpuoren5	21	13	tumors	tumor	NNS
cord-312340-hpuoren5	21	14	and	and	CC
cord-312340-hpuoren5	21	15	noted	note	VBD
cord-312340-hpuoren5	21	16	a	a	DT
cord-312340-hpuoren5	21	17	two	two	CD
cord-312340-hpuoren5	21	18	-	-	:
cord-312340-hpuoren5	21	19	fold	fold	VB
cord-312340-hpuoren5	21	20	higher	high	JJR
cord-312340-hpuoren5	21	21	risk	risk	NN
cord-312340-hpuoren5	21	22	of	of	IN
cord-312340-hpuoren5	21	23	SARS	SARS	NNP
cord-312340-hpuoren5	21	24	-	-	HYPH
cord-312340-hpuoren5	21	25	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	21	26	infection	infection	NN
cord-312340-hpuoren5	21	27	compared	compare	VBN
cord-312340-hpuoren5	21	28	to	to	IN
cord-312340-hpuoren5	21	29	the	the	DT
cord-312340-hpuoren5	21	30	overall	overall	JJ
cord-312340-hpuoren5	21	31	community	community	NN
cord-312340-hpuoren5	21	32	risk	risk	NN
cord-312340-hpuoren5	21	33	(	(	-LRB-
cord-312340-hpuoren5	21	34	1	1	CD
cord-312340-hpuoren5	21	35	)	)	-RRB-
cord-312340-hpuoren5	21	36	.	.	.
cord-312340-hpuoren5	22	1	These	these	DT
cord-312340-hpuoren5	22	2	patients	patient	NNS
cord-312340-hpuoren5	22	3	were	be	VBD
cord-312340-hpuoren5	22	4	more	more	RBR
cord-312340-hpuoren5	22	5	likely	likely	JJ
cord-312340-hpuoren5	22	6	to	to	TO
cord-312340-hpuoren5	22	7	require	require	VB
cord-312340-hpuoren5	22	8	the	the	DT
cord-312340-hpuoren5	22	9	intensive	intensive	JJ
cord-312340-hpuoren5	22	10	care	care	NN
cord-312340-hpuoren5	22	11	unit	unit	NN
cord-312340-hpuoren5	22	12	or	or	CC
cord-312340-hpuoren5	22	13	die	die	VB
cord-312340-hpuoren5	22	14	,	,	,
cord-312340-hpuoren5	22	15	compared	compare	VBN
cord-312340-hpuoren5	22	16	to	to	IN
cord-312340-hpuoren5	22	17	those	those	DT
cord-312340-hpuoren5	22	18	without	without	IN
cord-312340-hpuoren5	22	19	cancer	cancer	NN
cord-312340-hpuoren5	22	20	(	(	-LRB-
cord-312340-hpuoren5	22	21	39	39	CD
cord-312340-hpuoren5	22	22	%	%	NN
cord-312340-hpuoren5	22	23	vs	vs	IN
cord-312340-hpuoren5	22	24	8	8	CD
cord-312340-hpuoren5	22	25	%	%	NN
cord-312340-hpuoren5	22	26	,	,	,
cord-312340-hpuoren5	22	27	p	p	NN
cord-312340-hpuoren5	22	28	=	=	SYM
cord-312340-hpuoren5	22	29	0.0003	0.0003	CD
cord-312340-hpuoren5	22	30	)	)	-RRB-
cord-312340-hpuoren5	22	31	(	(	-LRB-
cord-312340-hpuoren5	22	32	1	1	CD
cord-312340-hpuoren5	22	33	)	)	-RRB-
cord-312340-hpuoren5	22	34	.	.	.
cord-312340-hpuoren5	23	1	Furthermore	furthermore	RB
cord-312340-hpuoren5	23	2	,	,	,
cord-312340-hpuoren5	23	3	patients	patient	NNS
cord-312340-hpuoren5	23	4	treated	treat	VBN
cord-312340-hpuoren5	23	5	with	with	IN
cord-312340-hpuoren5	23	6	chemotherapy	chemotherapy	NN
cord-312340-hpuoren5	23	7	within	within	IN
cord-312340-hpuoren5	23	8	a	a	DT
cord-312340-hpuoren5	23	9	month	month	NN
cord-312340-hpuoren5	23	10	of	of	IN
cord-312340-hpuoren5	23	11	COVID-19	covid-19	JJ
cord-312340-hpuoren5	23	12	infection	infection	NN
cord-312340-hpuoren5	23	13	experienced	experience	VBD
cord-312340-hpuoren5	23	14	a	a	DT
cord-312340-hpuoren5	23	15	5-fold	5-fold	CD
cord-312340-hpuoren5	23	16	risk	risk	NN
cord-312340-hpuoren5	23	17	of	of	IN
cord-312340-hpuoren5	23	18	severe	severe	JJ
cord-312340-hpuoren5	23	19	events	event	NNS
cord-312340-hpuoren5	23	20	compared	compare	VBN
cord-312340-hpuoren5	23	21	to	to	IN
cord-312340-hpuoren5	23	22	those	those	DT
cord-312340-hpuoren5	23	23	with	with	IN
cord-312340-hpuoren5	23	24	cancer	cancer	NN
cord-312340-hpuoren5	23	25	who	who	WP
cord-312340-hpuoren5	23	26	had	have	VBD
cord-312340-hpuoren5	23	27	not	not	RB
cord-312340-hpuoren5	23	28	received	receive	VBN
cord-312340-hpuoren5	23	29	recent	recent	JJ
cord-312340-hpuoren5	23	30	treatment	treatment	NN
cord-312340-hpuoren5	23	31	(	(	-LRB-
cord-312340-hpuoren5	23	32	1	1	CD
cord-312340-hpuoren5	23	33	)	)	-RRB-
cord-312340-hpuoren5	23	34	.	.	.
cord-312340-hpuoren5	24	1	A	a	DT
cord-312340-hpuoren5	24	2	report	report	NN
cord-312340-hpuoren5	24	3	of	of	IN
cord-312340-hpuoren5	24	4	218	218	CD
cord-312340-hpuoren5	24	5	oncology	oncology	NN
cord-312340-hpuoren5	24	6	patients	patient	NNS
cord-312340-hpuoren5	24	7	who	who	WP
cord-312340-hpuoren5	24	8	became	become	VBD
cord-312340-hpuoren5	24	9	infected	infected	JJ
cord-312340-hpuoren5	24	10	in	in	IN
cord-312340-hpuoren5	24	11	New	New	NNP
cord-312340-hpuoren5	24	12	York	York	NNP
cord-312340-hpuoren5	24	13	City	City	NNP
cord-312340-hpuoren5	24	14	noted	note	VBD
cord-312340-hpuoren5	24	15	a	a	DT
cord-312340-hpuoren5	24	16	case	case	NN
cord-312340-hpuoren5	24	17	fatality	fatality	NN
cord-312340-hpuoren5	24	18	rate	rate	NN
cord-312340-hpuoren5	24	19	of	of	IN
cord-312340-hpuoren5	24	20	28	28	CD
cord-312340-hpuoren5	24	21	%	%	NN
cord-312340-hpuoren5	24	22	(	(	-LRB-
cord-312340-hpuoren5	24	23	2	2	CD
cord-312340-hpuoren5	24	24	)	)	-RRB-
cord-312340-hpuoren5	24	25	.	.	.
cord-312340-hpuoren5	25	1	The	the	DT
cord-312340-hpuoren5	25	2	recognition	recognition	NN
cord-312340-hpuoren5	25	3	that	that	IN
cord-312340-hpuoren5	25	4	oncology	oncology	NN
cord-312340-hpuoren5	25	5	patients	patient	NNS
cord-312340-hpuoren5	25	6	are	be	VBP
cord-312340-hpuoren5	25	7	at	at	IN
cord-312340-hpuoren5	25	8	particularly	particularly	RB
cord-312340-hpuoren5	25	9	high	high	JJ
cord-312340-hpuoren5	25	10	risk	risk	NN
cord-312340-hpuoren5	25	11	for	for	IN
cord-312340-hpuoren5	25	12	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	25	13	complications	complication	NNS
cord-312340-hpuoren5	25	14	COVID-19	covid-19	VBP
cord-312340-hpuoren5	25	15	,	,	,
cord-312340-hpuoren5	25	16	as	as	RB
cord-312340-hpuoren5	25	17	well	well	RB
cord-312340-hpuoren5	25	18	as	as	IN
cord-312340-hpuoren5	25	19	the	the	DT
cord-312340-hpuoren5	25	20	strain	strain	NN
cord-312340-hpuoren5	25	21	that	that	IN
cord-312340-hpuoren5	25	22	the	the	DT
cord-312340-hpuoren5	25	23	pandemic	pandemic	NN
cord-312340-hpuoren5	25	24	has	have	VBZ
cord-312340-hpuoren5	25	25	placed	place	VBN
cord-312340-hpuoren5	25	26	on	on	IN
cord-312340-hpuoren5	25	27	healthcare	healthcare	NN
cord-312340-hpuoren5	25	28	resources	resource	NNS
cord-312340-hpuoren5	25	29	,	,	,
cord-312340-hpuoren5	25	30	has	have	VBZ
cord-312340-hpuoren5	25	31	led	lead	VBN
cord-312340-hpuoren5	25	32	to	to	IN
cord-312340-hpuoren5	25	33	rapid	rapid	JJ
cord-312340-hpuoren5	25	34	adjustments	adjustment	NNS
cord-312340-hpuoren5	25	35	in	in	IN
cord-312340-hpuoren5	25	36	the	the	DT
cord-312340-hpuoren5	25	37	management	management	NN
cord-312340-hpuoren5	25	38	of	of	IN
cord-312340-hpuoren5	25	39	these	these	DT
cord-312340-hpuoren5	25	40	patients	patient	NNS
cord-312340-hpuoren5	25	41	.	.	.
cord-312340-hpuoren5	26	1	There	there	EX
cord-312340-hpuoren5	26	2	has	have	VBZ
cord-312340-hpuoren5	26	3	been	be	VBN
cord-312340-hpuoren5	26	4	a	a	DT
cord-312340-hpuoren5	26	5	concerted	concerted	JJ
cord-312340-hpuoren5	26	6	effort	effort	NN
cord-312340-hpuoren5	26	7	to	to	TO
cord-312340-hpuoren5	26	8	minimize	minimize	VB
cord-312340-hpuoren5	26	9	patient	patient	JJ
cord-312340-hpuoren5	26	10	contact	contact	NN
cord-312340-hpuoren5	26	11	to	to	TO
cord-312340-hpuoren5	26	12	decrease	decrease	VB
cord-312340-hpuoren5	26	13	the	the	DT
cord-312340-hpuoren5	26	14	potential	potential	JJ
cord-312340-hpuoren5	26	15	exposure	exposure	NN
cord-312340-hpuoren5	26	16	of	of	IN
cord-312340-hpuoren5	26	17	patients	patient	NNS
cord-312340-hpuoren5	26	18	,	,	,
cord-312340-hpuoren5	26	19	caregivers	caregiver	NNS
cord-312340-hpuoren5	26	20	and	and	CC
cord-312340-hpuoren5	26	21	healthcare	healthcare	NN
cord-312340-hpuoren5	26	22	providers	provider	NNS
cord-312340-hpuoren5	26	23	to	to	IN
cord-312340-hpuoren5	26	24	SARS	SARS	NNP
cord-312340-hpuoren5	26	25	-	-	HYPH
cord-312340-hpuoren5	26	26	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	26	27	and	and	CC
cord-312340-hpuoren5	26	28	,	,	,
cord-312340-hpuoren5	26	29	in	in	IN
cord-312340-hpuoren5	26	30	some	some	DT
cord-312340-hpuoren5	26	31	hospitals	hospital	NNS
cord-312340-hpuoren5	26	32	,	,	,
cord-312340-hpuoren5	26	33	to	to	TO
cord-312340-hpuoren5	26	34	divert	divert	VB
cord-312340-hpuoren5	26	35	healthcare	healthcare	NN
cord-312340-hpuoren5	26	36	resources	resource	NNS
cord-312340-hpuoren5	26	37	towards	towards	IN
cord-312340-hpuoren5	26	38	the	the	DT
cord-312340-hpuoren5	26	39	care	care	NN
cord-312340-hpuoren5	26	40	of	of	IN
cord-312340-hpuoren5	26	41	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	26	42	patients	patient	NNS
cord-312340-hpuoren5	26	43	.	.	.
cord-312340-hpuoren5	27	1	Numerous	numerous	JJ
cord-312340-hpuoren5	27	2	publications	publication	NNS
cord-312340-hpuoren5	27	3	from	from	IN
cord-312340-hpuoren5	27	4	societies	society	NNS
cord-312340-hpuoren5	27	5	and	and	CC
cord-312340-hpuoren5	27	6	disease	disease	NN
cord-312340-hpuoren5	27	7	groups	group	NNS
cord-312340-hpuoren5	27	8	have	have	VBP
cord-312340-hpuoren5	27	9	made	make	VBN
cord-312340-hpuoren5	27	10	recommendations	recommendation	NNS
cord-312340-hpuoren5	27	11	for	for	IN
cord-312340-hpuoren5	27	12	how	how	WRB
cord-312340-hpuoren5	27	13	cancer	cancer	NN
cord-312340-hpuoren5	27	14	care	care	NN
cord-312340-hpuoren5	27	15	,	,	,
cord-312340-hpuoren5	27	16	including	include	VBG
cord-312340-hpuoren5	27	17	specific	specific	JJ
cord-312340-hpuoren5	27	18	chemotherapy	chemotherapy	NN
cord-312340-hpuoren5	27	19	regimens	regimen	NNS
cord-312340-hpuoren5	27	20	,	,	,
cord-312340-hpuoren5	27	21	should	should	MD
cord-312340-hpuoren5	27	22	be	be	VB
cord-312340-hpuoren5	27	23	adjusted	adjust	VBN
cord-312340-hpuoren5	27	24	(	(	-LRB-
cord-312340-hpuoren5	27	25	or	or	CC
cord-312340-hpuoren5	27	26	even	even	RB
cord-312340-hpuoren5	27	27	held	hold	VBN
cord-312340-hpuoren5	27	28	)	)	-RRB-
cord-312340-hpuoren5	27	29	during	during	IN
cord-312340-hpuoren5	27	30	the	the	DT
cord-312340-hpuoren5	27	31	pandemic	pandemic	NN
cord-312340-hpuoren5	27	32	.	.	.
cord-312340-hpuoren5	28	1	These	these	DT
cord-312340-hpuoren5	28	2	recommendations	recommendation	NNS
cord-312340-hpuoren5	28	3	are	be	VBP
cord-312340-hpuoren5	28	4	opinion	opinion	NN
cord-312340-hpuoren5	28	5	-	-	HYPH
cord-312340-hpuoren5	28	6	based	base	VBN
cord-312340-hpuoren5	28	7	but	but	CC
cord-312340-hpuoren5	28	8	not	not	RB
cord-312340-hpuoren5	28	9	evidence	evidence	NN
cord-312340-hpuoren5	28	10	-	-	HYPH
cord-312340-hpuoren5	28	11	based	base	VBN
cord-312340-hpuoren5	28	12	,	,	,
cord-312340-hpuoren5	28	13	as	as	IN
cord-312340-hpuoren5	28	14	at	at	IN
cord-312340-hpuoren5	28	15	this	this	DT
cord-312340-hpuoren5	28	16	point	point	NN
cord-312340-hpuoren5	28	17	it	-PRON-	PRP
cord-312340-hpuoren5	28	18	is	be	VBZ
cord-312340-hpuoren5	28	19	too	too	RB
cord-312340-hpuoren5	28	20	soon	soon	RB
cord-312340-hpuoren5	28	21	to	to	TO
cord-312340-hpuoren5	28	22	know	know	VB
cord-312340-hpuoren5	28	23	whether	whether	IN
cord-312340-hpuoren5	28	24	these	these	DT
cord-312340-hpuoren5	28	25	adjustments	adjustment	NNS
cord-312340-hpuoren5	28	26	protect	protect	VBP
cord-312340-hpuoren5	28	27	patients	patient	NNS
cord-312340-hpuoren5	28	28	from	from	IN
cord-312340-hpuoren5	28	29	COVID-19	covid-19	JJ
cord-312340-hpuoren5	28	30	complications	complication	NNS
cord-312340-hpuoren5	28	31	.	.	.
cord-312340-hpuoren5	29	1	For	for	IN
cord-312340-hpuoren5	29	2	example	example	NN
cord-312340-hpuoren5	29	3	,	,	,
cord-312340-hpuoren5	29	4	in	in	IN
cord-312340-hpuoren5	29	5	a	a	DT
cord-312340-hpuoren5	29	6	publication	publication	NN
cord-312340-hpuoren5	29	7	focused	focus	VBN
cord-312340-hpuoren5	29	8	on	on	IN
cord-312340-hpuoren5	29	9	the	the	DT
cord-312340-hpuoren5	29	10	management	management	NN
cord-312340-hpuoren5	29	11	of	of	IN
cord-312340-hpuoren5	29	12	patients	patient	NNS
cord-312340-hpuoren5	29	13	with	with	IN
cord-312340-hpuoren5	29	14	multiple	multiple	JJ
cord-312340-hpuoren5	29	15	myeloma	myeloma	NN
cord-312340-hpuoren5	29	16	during	during	IN
cord-312340-hpuoren5	29	17	the	the	DT
cord-312340-hpuoren5	29	18	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	29	19	pandemic	pandemic	NN
cord-312340-hpuoren5	29	20	,	,	,
cord-312340-hpuoren5	29	21	it	-PRON-	PRP
cord-312340-hpuoren5	29	22	was	be	VBD
cord-312340-hpuoren5	29	23	suggested	suggest	VBN
cord-312340-hpuoren5	29	24	that	that	IN
cord-312340-hpuoren5	29	25	daratumumab	daratumumab	NNP
cord-312340-hpuoren5	29	26	be	be	VB
cord-312340-hpuoren5	29	27	administered	administer	VBN
cord-312340-hpuoren5	29	28	every	every	DT
cord-312340-hpuoren5	29	29	four	four	CD
cord-312340-hpuoren5	29	30	weeks	week	NNS
cord-312340-hpuoren5	29	31	starting	start	VBG
cord-312340-hpuoren5	29	32	in	in	IN
cord-312340-hpuoren5	29	33	cycle	cycle	NN
cord-312340-hpuoren5	29	34	3	3	CD
cord-312340-hpuoren5	29	35	instead	instead	RB
cord-312340-hpuoren5	29	36	of	of	IN
cord-312340-hpuoren5	29	37	the	the	DT
cord-312340-hpuoren5	29	38	standard	standard	NN
cord-312340-hpuoren5	29	39	every	every	DT
cord-312340-hpuoren5	29	40	two	two	CD
cord-312340-hpuoren5	29	41	weeks	week	NNS
cord-312340-hpuoren5	29	42	schedule	schedule	NN
cord-312340-hpuoren5	29	43	(	(	-LRB-
cord-312340-hpuoren5	29	44	3	3	CD
cord-312340-hpuoren5	29	45	)	)	-RRB-
cord-312340-hpuoren5	29	46	.	.	.
cord-312340-hpuoren5	30	1	While	while	IN
cord-312340-hpuoren5	30	2	this	this	DT
cord-312340-hpuoren5	30	3	practice	practice	NN
cord-312340-hpuoren5	30	4	change	change	NN
cord-312340-hpuoren5	30	5	would	would	MD
cord-312340-hpuoren5	30	6	result	result	VB
cord-312340-hpuoren5	30	7	in	in	IN
cord-312340-hpuoren5	30	8	fewer	few	JJR
cord-312340-hpuoren5	30	9	infusion	infusion	NN
cord-312340-hpuoren5	30	10	center	center	NN
cord-312340-hpuoren5	30	11	visits	visit	NNS
cord-312340-hpuoren5	30	12	,	,	,
cord-312340-hpuoren5	30	13	there	there	EX
cord-312340-hpuoren5	30	14	are	be	VBP
cord-312340-hpuoren5	30	15	no	no	DT
cord-312340-hpuoren5	30	16	data	datum	NNS
cord-312340-hpuoren5	30	17	that	that	WDT
cord-312340-hpuoren5	30	18	enable	enable	VBP
cord-312340-hpuoren5	30	19	us	-PRON-	PRP
cord-312340-hpuoren5	30	20	to	to	TO
cord-312340-hpuoren5	30	21	estimate	estimate	VB
cord-312340-hpuoren5	30	22	the	the	DT
cord-312340-hpuoren5	30	23	resulting	result	VBG
cord-312340-hpuoren5	30	24	impact	impact	NN
cord-312340-hpuoren5	30	25	on	on	IN
cord-312340-hpuoren5	30	26	efficacy	efficacy	NN
cord-312340-hpuoren5	30	27	from	from	IN
cord-312340-hpuoren5	30	28	a	a	DT
cord-312340-hpuoren5	30	29	myeloma	myeloma	NN
cord-312340-hpuoren5	30	30	perspective	perspective	NN
cord-312340-hpuoren5	30	31	,	,	,
cord-312340-hpuoren5	30	32	on	on	IN
cord-312340-hpuoren5	30	33	degree	degree	NN
cord-312340-hpuoren5	30	34	of	of	IN
cord-312340-hpuoren5	30	35	immunosuppression	immunosuppression	NN
cord-312340-hpuoren5	30	36	or	or	CC
cord-312340-hpuoren5	30	37	on	on	IN
cord-312340-hpuoren5	30	38	COVID-19	covid-19	JJ
cord-312340-hpuoren5	30	39	severity	severity	NN
cord-312340-hpuoren5	30	40	.	.	.
cord-312340-hpuoren5	31	1	Early	early	RB
cord-312340-hpuoren5	31	2	in	in	IN
cord-312340-hpuoren5	31	3	the	the	DT
cord-312340-hpuoren5	31	4	pandemic	pandemic	NN
cord-312340-hpuoren5	31	5	,	,	,
cord-312340-hpuoren5	31	6	when	when	WRB
cord-312340-hpuoren5	31	7	it	-PRON-	PRP
cord-312340-hpuoren5	31	8	was	be	VBD
cord-312340-hpuoren5	31	9	predicted	predict	VBN
cord-312340-hpuoren5	31	10	that	that	IN
cord-312340-hpuoren5	31	11	the	the	DT
cord-312340-hpuoren5	31	12	surge	surge	NN
cord-312340-hpuoren5	31	13	from	from	IN
cord-312340-hpuoren5	31	14	the	the	DT
cord-312340-hpuoren5	31	15	first	first	JJ
cord-312340-hpuoren5	31	16	wave	wave	NN
cord-312340-hpuoren5	31	17	would	would	MD
cord-312340-hpuoren5	31	18	be	be	VB
cord-312340-hpuoren5	31	19	swift	swift	JJ
cord-312340-hpuoren5	31	20	,	,	,
cord-312340-hpuoren5	31	21	it	-PRON-	PRP
cord-312340-hpuoren5	31	22	was	be	VBD
cord-312340-hpuoren5	31	23	relatively	relatively	RB
cord-312340-hpuoren5	31	24	simple	simple	JJ
cord-312340-hpuoren5	31	25	to	to	TO
cord-312340-hpuoren5	31	26	make	make	VB
cord-312340-hpuoren5	31	27	treatment	treatment	NN
cord-312340-hpuoren5	31	28	decisions	decision	NNS
cord-312340-hpuoren5	31	29	such	such	JJ
cord-312340-hpuoren5	31	30	as	as	IN
cord-312340-hpuoren5	31	31	holding	hold	VBG
cord-312340-hpuoren5	31	32	some	some	DT
cord-312340-hpuoren5	31	33	or	or	CC
cord-312340-hpuoren5	31	34	all	all	DT
cord-312340-hpuoren5	31	35	of	of	IN
cord-312340-hpuoren5	31	36	a	a	DT
cord-312340-hpuoren5	31	37	cycle	cycle	NN
cord-312340-hpuoren5	31	38	of	of	IN
cord-312340-hpuoren5	31	39	chemotherapy	chemotherapy	NN
cord-312340-hpuoren5	31	40	or	or	CC
cord-312340-hpuoren5	31	41	postponing	postpone	VBG
cord-312340-hpuoren5	31	42	SCT	SCT	NNP
cord-312340-hpuoren5	31	43	if	if	IN
cord-312340-hpuoren5	31	44	the	the	DT
cord-312340-hpuoren5	31	45	intent	intent	NN
cord-312340-hpuoren5	31	46	was	be	VBD
cord-312340-hpuoren5	31	47	not	not	RB
cord-312340-hpuoren5	31	48	curative	curative	JJ
cord-312340-hpuoren5	31	49	.	.	.
cord-312340-hpuoren5	32	1	However	however	RB
cord-312340-hpuoren5	32	2	,	,	,
cord-312340-hpuoren5	32	3	it	-PRON-	PRP
cord-312340-hpuoren5	32	4	is	be	VBZ
cord-312340-hpuoren5	32	5	becoming	become	VBG
cord-312340-hpuoren5	32	6	evident	evident	JJ
cord-312340-hpuoren5	32	7	that	that	IN
cord-312340-hpuoren5	32	8	this	this	DT
cord-312340-hpuoren5	32	9	approach	approach	NN
cord-312340-hpuoren5	32	10	can	can	MD
cord-312340-hpuoren5	32	11	not	not	RB
cord-312340-hpuoren5	32	12	be	be	VB
cord-312340-hpuoren5	32	13	continued	continue	VBN
cord-312340-hpuoren5	32	14	indefinitely	indefinitely	RB
cord-312340-hpuoren5	32	15	and	and	CC
cord-312340-hpuoren5	32	16	therefore	therefore	RB
cord-312340-hpuoren5	32	17	the	the	DT
cord-312340-hpuoren5	32	18	risk	risk	NN
cord-312340-hpuoren5	32	19	:	:	:
cord-312340-hpuoren5	32	20	benefit	benefit	NN
cord-312340-hpuoren5	32	21	calculation	calculation	NN
cord-312340-hpuoren5	32	22	must	must	MD
cord-312340-hpuoren5	32	23	incorporate	incorporate	VB
cord-312340-hpuoren5	32	24	not	not	RB
cord-312340-hpuoren5	32	25	only	only	RB
cord-312340-hpuoren5	32	26	the	the	DT
cord-312340-hpuoren5	32	27	risk	risk	NN
cord-312340-hpuoren5	32	28	of	of	IN
cord-312340-hpuoren5	32	29	potential	potential	JJ
cord-312340-hpuoren5	32	30	SARS	SARS	NNP
cord-312340-hpuoren5	32	31	-	-	HYPH
cord-312340-hpuoren5	32	32	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	32	33	infection	infection	NN
cord-312340-hpuoren5	32	34	,	,	,
cord-312340-hpuoren5	32	35	but	but	CC
cord-312340-hpuoren5	32	36	also	also	RB
cord-312340-hpuoren5	32	37	the	the	DT
cord-312340-hpuoren5	32	38	long	long	JJ
cord-312340-hpuoren5	32	39	-	-	HYPH
cord-312340-hpuoren5	32	40	term	term	NN
cord-312340-hpuoren5	32	41	risks	risk	NNS
cord-312340-hpuoren5	32	42	of	of	IN
cord-312340-hpuoren5	32	43	making	make	VBG
cord-312340-hpuoren5	32	44	significant	significant	JJ
cord-312340-hpuoren5	32	45	adjustments	adjustment	NNS
cord-312340-hpuoren5	32	46	to	to	IN
cord-312340-hpuoren5	32	47	standard	standard	NN
cord-312340-hpuoren5	32	48	of	of	IN
cord-312340-hpuoren5	32	49	care	care	NN
cord-312340-hpuoren5	32	50	chemotherapy	chemotherapy	NN
cord-312340-hpuoren5	32	51	practices	practice	NNS
cord-312340-hpuoren5	32	52	.	.	.
cord-312340-hpuoren5	33	1	With	with	IN
cord-312340-hpuoren5	33	2	multiple	multiple	JJ
cord-312340-hpuoren5	33	3	second	second	JJ
cord-312340-hpuoren5	33	4	waves	wave	NNS
cord-312340-hpuoren5	33	5	now	now	RB
cord-312340-hpuoren5	33	6	being	be	VBG
cord-312340-hpuoren5	33	7	predicted	predict	VBN
cord-312340-hpuoren5	33	8	,	,	,
cord-312340-hpuoren5	33	9	we	-PRON-	PRP
cord-312340-hpuoren5	33	10	must	must	MD
cord-312340-hpuoren5	33	11	learn	learn	VB
cord-312340-hpuoren5	33	12	to	to	TO
cord-312340-hpuoren5	33	13	practice	practice	VB
cord-312340-hpuoren5	33	14	optimal	optimal	JJ
cord-312340-hpuoren5	33	15	oncology	oncology	NN
cord-312340-hpuoren5	33	16	care	care	NN
cord-312340-hpuoren5	33	17	including	include	VBG
cord-312340-hpuoren5	33	18	the	the	DT
cord-312340-hpuoren5	33	19	added	add	VBN
cord-312340-hpuoren5	33	20	risks	risk	NNS
cord-312340-hpuoren5	33	21	of	of	IN
cord-312340-hpuoren5	33	22	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	33	23	.	.	.
cord-312340-hpuoren5	34	1	Clinical	clinical	JJ
cord-312340-hpuoren5	34	2	trials	trial	NNS
cord-312340-hpuoren5	34	3	are	be	VBP
cord-312340-hpuoren5	34	4	a	a	DT
cord-312340-hpuoren5	34	5	critical	critical	JJ
cord-312340-hpuoren5	34	6	component	component	NN
cord-312340-hpuoren5	34	7	of	of	IN
cord-312340-hpuoren5	34	8	oncology	oncology	NN
cord-312340-hpuoren5	34	9	care	care	NN
cord-312340-hpuoren5	34	10	.	.	.
cord-312340-hpuoren5	35	1	It	-PRON-	PRP
cord-312340-hpuoren5	35	2	is	be	VBZ
cord-312340-hpuoren5	35	3	estimated	estimate	VBN
cord-312340-hpuoren5	35	4	that	that	IN
cord-312340-hpuoren5	35	5	only	only	RB
cord-312340-hpuoren5	35	6	5	5	CD
cord-312340-hpuoren5	35	7	-	-	SYM
cord-312340-hpuoren5	35	8	10	10	CD
cord-312340-hpuoren5	35	9	%	%	NN
cord-312340-hpuoren5	35	10	of	of	IN
cord-312340-hpuoren5	35	11	all	all	DT
cord-312340-hpuoren5	35	12	patients	patient	NNS
cord-312340-hpuoren5	35	13	with	with	IN
cord-312340-hpuoren5	35	14	cancer	cancer	NN
cord-312340-hpuoren5	35	15	in	in	IN
cord-312340-hpuoren5	35	16	the	the	DT
cord-312340-hpuoren5	35	17	US	US	NNP
cord-312340-hpuoren5	35	18	participate	participate	VB
cord-312340-hpuoren5	35	19	in	in	IN
cord-312340-hpuoren5	35	20	therapeutic	therapeutic	JJ
cord-312340-hpuoren5	35	21	clinical	clinical	JJ
cord-312340-hpuoren5	35	22	trials	trial	NNS
cord-312340-hpuoren5	35	23	(	(	-LRB-
cord-312340-hpuoren5	35	24	4	4	CD
cord-312340-hpuoren5	35	25	)	)	-RRB-
cord-312340-hpuoren5	35	26	.	.	.
cord-312340-hpuoren5	36	1	Despite	despite	IN
cord-312340-hpuoren5	36	2	the	the	DT
cord-312340-hpuoren5	36	3	barriers	barrier	NNS
cord-312340-hpuoren5	36	4	that	that	WDT
cord-312340-hpuoren5	36	5	lead	lead	VBP
cord-312340-hpuoren5	36	6	to	to	IN
cord-312340-hpuoren5	36	7	this	this	DT
cord-312340-hpuoren5	36	8	low	low	JJ
cord-312340-hpuoren5	36	9	rate	rate	NN
cord-312340-hpuoren5	36	10	of	of	IN
cord-312340-hpuoren5	36	11	participation	participation	NN
cord-312340-hpuoren5	36	12	,	,	,
cord-312340-hpuoren5	36	13	clinical	clinical	JJ
cord-312340-hpuoren5	36	14	trials	trial	NNS
cord-312340-hpuoren5	36	15	remain	remain	VBP
cord-312340-hpuoren5	36	16	the	the	DT
cord-312340-hpuoren5	36	17	cornerstone	cornerstone	NN
cord-312340-hpuoren5	36	18	for	for	IN
cord-312340-hpuoren5	36	19	improving	improve	VBG
cord-312340-hpuoren5	36	20	oncology	oncology	NN
cord-312340-hpuoren5	36	21	patient	patient	NN
cord-312340-hpuoren5	36	22	outcomes	outcome	NNS
cord-312340-hpuoren5	36	23	through	through	IN
cord-312340-hpuoren5	36	24	the	the	DT
cord-312340-hpuoren5	36	25	development	development	NN
cord-312340-hpuoren5	36	26	of	of	IN
cord-312340-hpuoren5	36	27	new	new	JJ
cord-312340-hpuoren5	36	28	therapies	therapy	NNS
cord-312340-hpuoren5	36	29	.	.	.
cord-312340-hpuoren5	37	1	An	an	DT
cord-312340-hpuoren5	37	2	analysis	analysis	NN
cord-312340-hpuoren5	37	3	of	of	IN
cord-312340-hpuoren5	37	4	accrual	accrual	NN
cord-312340-hpuoren5	37	5	data	datum	NNS
cord-312340-hpuoren5	37	6	for	for	IN
cord-312340-hpuoren5	37	7	national	national	JJ
cord-312340-hpuoren5	37	8	cancer	cancer	NN
cord-312340-hpuoren5	37	9	treatment	treatment	NN
cord-312340-hpuoren5	37	10	trials	trial	NNS
cord-312340-hpuoren5	37	11	revealed	reveal	VBD
cord-312340-hpuoren5	37	12	a	a	DT
cord-312340-hpuoren5	37	13	correlation	correlation	NN
cord-312340-hpuoren5	37	14	between	between	IN
cord-312340-hpuoren5	37	15	trial	trial	NN
cord-312340-hpuoren5	37	16	enrollment	enrollment	NN
cord-312340-hpuoren5	37	17	and	and	CC
cord-312340-hpuoren5	37	18	5-year	5-year	CD
cord-312340-hpuoren5	37	19	cancer	cancer	NN
cord-312340-hpuoren5	37	20	-	-	HYPH
cord-312340-hpuoren5	37	21	specific	specific	JJ
cord-312340-hpuoren5	37	22	survival	survival	NN
cord-312340-hpuoren5	37	23	rates	rate	NNS
cord-312340-hpuoren5	37	24	(	(	-LRB-
cord-312340-hpuoren5	37	25	4	4	CD
cord-312340-hpuoren5	37	26	)	)	-RRB-
cord-312340-hpuoren5	37	27	.	.	.
cord-312340-hpuoren5	38	1	The	the	DT
cord-312340-hpuoren5	38	2	conduct	conduct	NN
cord-312340-hpuoren5	38	3	of	of	IN
cord-312340-hpuoren5	38	4	clinical	clinical	JJ
cord-312340-hpuoren5	38	5	trials	trial	NNS
cord-312340-hpuoren5	38	6	has	have	VBZ
cord-312340-hpuoren5	38	7	become	become	VBN
cord-312340-hpuoren5	38	8	increasingly	increasingly	RB
cord-312340-hpuoren5	38	9	complicated	complicated	JJ
cord-312340-hpuoren5	38	10	in	in	IN
cord-312340-hpuoren5	38	11	the	the	DT
cord-312340-hpuoren5	38	12	era	era	NN
cord-312340-hpuoren5	38	13	of	of	IN
cord-312340-hpuoren5	38	14	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	38	15	,	,	,
cord-312340-hpuoren5	38	16	significantly	significantly	RB
cord-312340-hpuoren5	38	17	restricting	restrict	VBG
cord-312340-hpuoren5	38	18	access	access	NN
cord-312340-hpuoren5	38	19	of	of	IN
cord-312340-hpuoren5	38	20	clinical	clinical	JJ
cord-312340-hpuoren5	38	21	trials	trial	NNS
cord-312340-hpuoren5	38	22	to	to	IN
cord-312340-hpuoren5	38	23	oncology	oncology	NN
cord-312340-hpuoren5	38	24	patients	patient	NNS
cord-312340-hpuoren5	38	25	.	.	.
cord-312340-hpuoren5	39	1	Underlying	underlying	JJ
cord-312340-hpuoren5	39	2	factors	factor	NNS
cord-312340-hpuoren5	39	3	include	include	VBP
cord-312340-hpuoren5	39	4	the	the	DT
cord-312340-hpuoren5	39	5	desire	desire	NN
cord-312340-hpuoren5	39	6	to	to	TO
cord-312340-hpuoren5	39	7	limit	limit	VB
cord-312340-hpuoren5	39	8	patient	patient	JJ
cord-312340-hpuoren5	39	9	contact	contact	NN
cord-312340-hpuoren5	39	10	to	to	TO
cord-312340-hpuoren5	39	11	decrease	decrease	VB
cord-312340-hpuoren5	39	12	SARS	SARS	NNP
cord-312340-hpuoren5	39	13	-	-	HYPH
cord-312340-hpuoren5	39	14	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	39	15	exposure	exposure	NN
cord-312340-hpuoren5	39	16	,	,	,
cord-312340-hpuoren5	39	17	research	research	NN
cord-312340-hpuoren5	39	18	personnel	personnel	NNS
cord-312340-hpuoren5	39	19	being	be	VBG
cord-312340-hpuoren5	39	20	required	require	VBN
cord-312340-hpuoren5	39	21	to	to	TO
cord-312340-hpuoren5	39	22	work	work	VB
cord-312340-hpuoren5	39	23	from	from	IN
cord-312340-hpuoren5	39	24	home	home	NN
cord-312340-hpuoren5	39	25	,	,	,
cord-312340-hpuoren5	39	26	travel	travel	NN
cord-312340-hpuoren5	39	27	bans	ban	NNS
cord-312340-hpuoren5	39	28	,	,	,
cord-312340-hpuoren5	39	29	concern	concern	NN
cord-312340-hpuoren5	39	30	about	about	IN
cord-312340-hpuoren5	39	31	the	the	DT
cord-312340-hpuoren5	39	32	unknown	unknown	JJ
cord-312340-hpuoren5	39	33	impact	impact	NN
cord-312340-hpuoren5	39	34	of	of	IN
cord-312340-hpuoren5	39	35	investigational	investigational	JJ
cord-312340-hpuoren5	39	36	therapy	therapy	NN
cord-312340-hpuoren5	39	37	on	on	IN
cord-312340-hpuoren5	39	38	severity	severity	NN
cord-312340-hpuoren5	39	39	of	of	IN
cord-312340-hpuoren5	39	40	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	39	41	,	,	,
cord-312340-hpuoren5	39	42	as	as	RB
cord-312340-hpuoren5	39	43	well	well	RB
cord-312340-hpuoren5	39	44	as	as	IN
cord-312340-hpuoren5	39	45	healthcare	healthcare	NN
cord-312340-hpuoren5	39	46	resources	resource	NNS
cord-312340-hpuoren5	39	47	being	be	VBG
cord-312340-hpuoren5	39	48	diverted	divert	VBN
cord-312340-hpuoren5	39	49	to	to	IN
cord-312340-hpuoren5	39	50	the	the	DT
cord-312340-hpuoren5	39	51	management	management	NN
cord-312340-hpuoren5	39	52	of	of	IN
cord-312340-hpuoren5	39	53	patients	patient	NNS
cord-312340-hpuoren5	39	54	with	with	IN
cord-312340-hpuoren5	39	55	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	39	56	.	.	.
cord-312340-hpuoren5	40	1	Industry	industry	NN
cord-312340-hpuoren5	40	2	sponsors	sponsor	NNS
cord-312340-hpuoren5	40	3	and	and	CC
cord-312340-hpuoren5	40	4	institutions	institution	NNS
cord-312340-hpuoren5	40	5	have	have	VBP
cord-312340-hpuoren5	40	6	placed	place	VBN
cord-312340-hpuoren5	40	7	selected	select	VBN
cord-312340-hpuoren5	40	8	studies	study	NNS
cord-312340-hpuoren5	40	9	on	on	IN
cord-312340-hpuoren5	40	10	hold	hold	NN
cord-312340-hpuoren5	40	11	and/or	and/or	CC
cord-312340-hpuoren5	40	12	halted	halted	JJ
cord-312340-hpuoren5	40	13	enrollment	enrollment	NN
cord-312340-hpuoren5	40	14	.	.	.
cord-312340-hpuoren5	41	1	A	a	DT
cord-312340-hpuoren5	41	2	recent	recent	JJ
cord-312340-hpuoren5	41	3	survey	survey	NN
cord-312340-hpuoren5	41	4	conducted	conduct	VBN
cord-312340-hpuoren5	41	5	by	by	IN
cord-312340-hpuoren5	41	6	the	the	DT
cord-312340-hpuoren5	41	7	American	American	NNP
cord-312340-hpuoren5	41	8	Society	Society	NNP
cord-312340-hpuoren5	41	9	of	of	IN
cord-312340-hpuoren5	41	10	Clinical	Clinical	NNP
cord-312340-hpuoren5	41	11	Oncology	Oncology	NNP
cord-312340-hpuoren5	41	12	(	(	-LRB-
cord-312340-hpuoren5	41	13	ASCO	ASCO	NNP
cord-312340-hpuoren5	41	14	)	)	-RRB-
cord-312340-hpuoren5	41	15	revealed	reveal	VBD
cord-312340-hpuoren5	41	16	that	that	IN
cord-312340-hpuoren5	41	17	almost	almost	RB
cord-312340-hpuoren5	41	18	sixty	sixty	CD
cord-312340-hpuoren5	41	19	percent	percent	NN
cord-312340-hpuoren5	41	20	of	of	IN
cord-312340-hpuoren5	41	21	respondents	respondent	NNS
cord-312340-hpuoren5	41	22	(	(	-LRB-
cord-312340-hpuoren5	41	23	from	from	IN
cord-312340-hpuoren5	41	24	both	both	CC
cord-312340-hpuoren5	41	25	academic	academic	JJ
cord-312340-hpuoren5	41	26	and	and	CC
cord-312340-hpuoren5	41	27	community	community	NN
cord-312340-hpuoren5	41	28	-	-	HYPH
cord-312340-hpuoren5	41	29	based	base	VBN
cord-312340-hpuoren5	41	30	programs	program	NNS
cord-312340-hpuoren5	41	31	)	)	-RRB-
cord-312340-hpuoren5	41	32	had	have	VBD
cord-312340-hpuoren5	41	33	halted	halt	VBN
cord-312340-hpuoren5	41	34	screening	screening	NN
cord-312340-hpuoren5	41	35	and/or	and/or	CC
cord-312340-hpuoren5	41	36	enrollment	enrollment	NN
cord-312340-hpuoren5	41	37	of	of	IN
cord-312340-hpuoren5	41	38	clinical	clinical	JJ
cord-312340-hpuoren5	41	39	trials	trial	NNS
cord-312340-hpuoren5	41	40	(	(	-LRB-
cord-312340-hpuoren5	41	41	5	5	CD
cord-312340-hpuoren5	41	42	)	)	-RRB-
cord-312340-hpuoren5	41	43	.	.	.
cord-312340-hpuoren5	42	1	Some	some	DT
cord-312340-hpuoren5	42	2	institutions	institution	NNS
cord-312340-hpuoren5	42	3	have	have	VBP
cord-312340-hpuoren5	42	4	encouraged	encourage	VBN
cord-312340-hpuoren5	42	5	investigators	investigator	NNS
cord-312340-hpuoren5	42	6	to	to	TO
cord-312340-hpuoren5	42	7	remove	remove	VB
cord-312340-hpuoren5	42	8	subjects	subject	NNS
cord-312340-hpuoren5	42	9	from	from	IN
cord-312340-hpuoren5	42	10	ongoing	ongoing	JJ
cord-312340-hpuoren5	42	11	studies	study	NNS
cord-312340-hpuoren5	42	12	.	.	.
cord-312340-hpuoren5	43	1	In	in	IN
cord-312340-hpuoren5	43	2	other	other	JJ
cord-312340-hpuoren5	43	3	situations	situation	NNS
cord-312340-hpuoren5	43	4	,	,	,
cord-312340-hpuoren5	43	5	institutions	institution	NNS
cord-312340-hpuoren5	43	6	have	have	VBP
cord-312340-hpuoren5	43	7	mandated	mandate	VBN
cord-312340-hpuoren5	43	8	that	that	IN
cord-312340-hpuoren5	43	9	only	only	JJ
cord-312340-hpuoren5	43	10	standard	standard	NN
cord-312340-hpuoren5	43	11	of	of	IN
cord-312340-hpuoren5	43	12	care	care	NN
cord-312340-hpuoren5	43	13	procedures	procedure	NNS
cord-312340-hpuoren5	43	14	be	be	VB
cord-312340-hpuoren5	43	15	allowed	allow	VBN
cord-312340-hpuoren5	43	16	and	and	CC
cord-312340-hpuoren5	43	17	that	that	IN
cord-312340-hpuoren5	43	18	study	study	NN
cord-312340-hpuoren5	43	19	-	-	HYPH
cord-312340-hpuoren5	43	20	specific	specific	JJ
cord-312340-hpuoren5	43	21	procedures	procedure	NNS
cord-312340-hpuoren5	43	22	cease	cease	VBP
cord-312340-hpuoren5	43	23	.	.	.
cord-312340-hpuoren5	44	1	The	the	DT
cord-312340-hpuoren5	44	2	ASCO	ASCO	NNP
cord-312340-hpuoren5	44	3	survey	survey	NN
cord-312340-hpuoren5	44	4	revealed	reveal	VBD
cord-312340-hpuoren5	44	5	that	that	IN
cord-312340-hpuoren5	44	6	half	half	NN
cord-312340-hpuoren5	44	7	of	of	IN
cord-312340-hpuoren5	44	8	respondents	respondent	NNS
cord-312340-hpuoren5	44	9	reported	report	VBD
cord-312340-hpuoren5	44	10	that	that	IN
cord-312340-hpuoren5	44	11	their	-PRON-	PRP$
cord-312340-hpuoren5	44	12	sites	site	NNS
cord-312340-hpuoren5	44	13	had	have	VBD
cord-312340-hpuoren5	44	14	stopped	stop	VBN
cord-312340-hpuoren5	44	15	collecting	collect	VBG
cord-312340-hpuoren5	44	16	research	research	NN
cord-312340-hpuoren5	44	17	-	-	HYPH
cord-312340-hpuoren5	44	18	only	only	RB
cord-312340-hpuoren5	44	19	blood	blood	NN
cord-312340-hpuoren5	44	20	and/or	and/or	CC
cord-312340-hpuoren5	44	21	tissue	tissue	NN
cord-312340-hpuoren5	44	22	samples	sample	NNS
cord-312340-hpuoren5	44	23	(	(	-LRB-
cord-312340-hpuoren5	44	24	5	5	CD
cord-312340-hpuoren5	44	25	)	)	-RRB-
cord-312340-hpuoren5	44	26	.	.	.
cord-312340-hpuoren5	45	1	Some	some	DT
cord-312340-hpuoren5	45	2	institutions	institution	NNS
cord-312340-hpuoren5	45	3	have	have	VBP
cord-312340-hpuoren5	45	4	halted	halt	VBN
cord-312340-hpuoren5	45	5	the	the	DT
cord-312340-hpuoren5	45	6	internal	internal	JJ
cord-312340-hpuoren5	45	7	regulatory	regulatory	JJ
cord-312340-hpuoren5	45	8	process	process	NN
cord-312340-hpuoren5	45	9	that	that	WDT
cord-312340-hpuoren5	45	10	is	be	VBZ
cord-312340-hpuoren5	45	11	necessary	necessary	JJ
cord-312340-hpuoren5	45	12	for	for	IN
cord-312340-hpuoren5	45	13	new	new	JJ
cord-312340-hpuoren5	45	14	studies	study	NNS
cord-312340-hpuoren5	45	15	to	to	TO
cord-312340-hpuoren5	45	16	open	open	VB
cord-312340-hpuoren5	45	17	.	.	.
cord-312340-hpuoren5	46	1	Some	some	DT
cord-312340-hpuoren5	46	2	sponsors	sponsor	NNS
cord-312340-hpuoren5	46	3	have	have	VBP
cord-312340-hpuoren5	46	4	halted	halt	VBN
cord-312340-hpuoren5	46	5	the	the	DT
cord-312340-hpuoren5	46	6	internal	internal	JJ
cord-312340-hpuoren5	46	7	review	review	NN
cord-312340-hpuoren5	46	8	process	process	NN
cord-312340-hpuoren5	46	9	that	that	WDT
cord-312340-hpuoren5	46	10	evaluates	evaluate	VBZ
cord-312340-hpuoren5	46	11	new	new	JJ
cord-312340-hpuoren5	46	12	investigatorinitiated	investigatorinitiated	JJ
cord-312340-hpuoren5	46	13	trial	trial	NN
cord-312340-hpuoren5	46	14	concepts	concept	NNS
cord-312340-hpuoren5	46	15	.	.	.
cord-312340-hpuoren5	47	1	As	as	IN
cord-312340-hpuoren5	47	2	a	a	DT
cord-312340-hpuoren5	47	3	whole	whole	NN
cord-312340-hpuoren5	47	4	,	,	,
cord-312340-hpuoren5	47	5	these	these	DT
cord-312340-hpuoren5	47	6	measures	measure	NNS
cord-312340-hpuoren5	47	7	have	have	VBP
cord-312340-hpuoren5	47	8	led	lead	VBN
cord-312340-hpuoren5	47	9	to	to	IN
cord-312340-hpuoren5	47	10	significant	significant	JJ
cord-312340-hpuoren5	47	11	changes	change	NNS
cord-312340-hpuoren5	47	12	in	in	IN
cord-312340-hpuoren5	47	13	the	the	DT
cord-312340-hpuoren5	47	14	clinical	clinical	JJ
cord-312340-hpuoren5	47	15	trial	trial	NN
cord-312340-hpuoren5	47	16	enterprise	enterprise	NN
cord-312340-hpuoren5	47	17	.	.	.
cord-312340-hpuoren5	48	1	Table	table	NN
cord-312340-hpuoren5	48	2	1	1	CD
cord-312340-hpuoren5	48	3	provides	provide	VBZ
cord-312340-hpuoren5	48	4	an	an	DT
cord-312340-hpuoren5	48	5	overview	overview	NN
cord-312340-hpuoren5	48	6	of	of	IN
cord-312340-hpuoren5	48	7	some	some	DT
cord-312340-hpuoren5	48	8	key	key	JJ
cord-312340-hpuoren5	48	9	clinical	clinical	JJ
cord-312340-hpuoren5	48	10	trial	trial	NN
cord-312340-hpuoren5	48	11	practices	practice	NNS
cord-312340-hpuoren5	48	12	,	,	,
cord-312340-hpuoren5	48	13	including	include	VBG
cord-312340-hpuoren5	48	14	the	the	DT
cord-312340-hpuoren5	48	15	pre	pre	JJ
cord-312340-hpuoren5	48	16	-	-	JJ
cord-312340-hpuoren5	48	17	COVID-19	covid-19	JJ
cord-312340-hpuoren5	48	18	era	era	NN
cord-312340-hpuoren5	48	19	,	,	,
cord-312340-hpuoren5	48	20	the	the	DT
cord-312340-hpuoren5	48	21	current	current	JJ
cord-312340-hpuoren5	48	22	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	48	23	era	era	NN
cord-312340-hpuoren5	48	24	,	,	,
cord-312340-hpuoren5	48	25	as	as	RB
cord-312340-hpuoren5	48	26	well	well	RB
cord-312340-hpuoren5	48	27	as	as	IN
cord-312340-hpuoren5	48	28	speculations	speculation	NNS
cord-312340-hpuoren5	48	29	about	about	IN
cord-312340-hpuoren5	48	30	what	what	WP
cord-312340-hpuoren5	48	31	the	the	DT
cord-312340-hpuoren5	48	32	future	future	NN
cord-312340-hpuoren5	48	33	might	may	MD
cord-312340-hpuoren5	48	34	entail	entail	VB
cord-312340-hpuoren5	48	35	.	.	.
cord-312340-hpuoren5	49	1	Some	some	DT
cord-312340-hpuoren5	49	2	of	of	IN
cord-312340-hpuoren5	49	3	these	these	DT
cord-312340-hpuoren5	49	4	practice	practice	NN
cord-312340-hpuoren5	49	5	This	this	DT
cord-312340-hpuoren5	49	6	article	article	NN
cord-312340-hpuoren5	49	7	is	be	VBZ
cord-312340-hpuoren5	49	8	protected	protect	VBN
cord-312340-hpuoren5	49	9	by	by	IN
cord-312340-hpuoren5	49	10	copyright	copyright	NN
cord-312340-hpuoren5	49	11	.	.	.
cord-312340-hpuoren5	50	1	All	all	DT
cord-312340-hpuoren5	50	2	rights	right	NNS
cord-312340-hpuoren5	50	3	reserved	reserve	VBN
cord-312340-hpuoren5	50	4	changes	change	NNS
cord-312340-hpuoren5	50	5	,	,	,
cord-312340-hpuoren5	50	6	including	include	VBG
cord-312340-hpuoren5	50	7	the	the	DT
cord-312340-hpuoren5	50	8	use	use	NN
cord-312340-hpuoren5	50	9	of	of	IN
cord-312340-hpuoren5	50	10	telehealth	telehealth	NN
cord-312340-hpuoren5	50	11	visits	visit	NNS
cord-312340-hpuoren5	50	12	,	,	,
cord-312340-hpuoren5	50	13	electronic	electronic	JJ
cord-312340-hpuoren5	50	14	informed	informed	JJ
cord-312340-hpuoren5	50	15	consents	consent	NNS
cord-312340-hpuoren5	50	16	and	and	CC
cord-312340-hpuoren5	50	17	delivery	delivery	NN
cord-312340-hpuoren5	50	18	of	of	IN
cord-312340-hpuoren5	50	19	study	study	NN
cord-312340-hpuoren5	50	20	medications	medication	NNS
cord-312340-hpuoren5	50	21	to	to	IN
cord-312340-hpuoren5	50	22	the	the	DT
cord-312340-hpuoren5	50	23	home	home	NN
cord-312340-hpuoren5	50	24	,	,	,
cord-312340-hpuoren5	50	25	will	will	MD
cord-312340-hpuoren5	50	26	hopefully	hopefully	RB
cord-312340-hpuoren5	50	27	become	become	VB
cord-312340-hpuoren5	50	28	permanent	permanent	JJ
cord-312340-hpuoren5	50	29	additions	addition	NNS
cord-312340-hpuoren5	50	30	in	in	IN
cord-312340-hpuoren5	50	31	the	the	DT
cord-312340-hpuoren5	50	32	post	post	JJ
cord-312340-hpuoren5	50	33	-	-	JJ
cord-312340-hpuoren5	50	34	pandemic	pandemic	JJ
cord-312340-hpuoren5	50	35	era	era	NN
cord-312340-hpuoren5	50	36	,	,	,
cord-312340-hpuoren5	50	37	resulting	result	VBG
cord-312340-hpuoren5	50	38	in	in	IN
cord-312340-hpuoren5	50	39	enhanced	enhance	VBN
cord-312340-hpuoren5	50	40	accrual	accrual	NN
cord-312340-hpuoren5	50	41	and	and	CC
cord-312340-hpuoren5	50	42	retention	retention	NN
cord-312340-hpuoren5	50	43	.	.	.
cord-312340-hpuoren5	51	1	There	there	EX
cord-312340-hpuoren5	51	2	is	be	VBZ
cord-312340-hpuoren5	51	3	opportunity	opportunity	NN
cord-312340-hpuoren5	51	4	to	to	TO
cord-312340-hpuoren5	51	5	incorporate	incorporate	VB
cord-312340-hpuoren5	51	6	secure	secure	JJ
cord-312340-hpuoren5	51	7	online	online	JJ
cord-312340-hpuoren5	51	8	consenting	consent	VBG
cord-312340-hpuoren5	51	9	processes	process	NNS
cord-312340-hpuoren5	51	10	and	and	CC
cord-312340-hpuoren5	51	11	remote	remote	JJ
cord-312340-hpuoren5	51	12	monitoring	monitoring	NN
cord-312340-hpuoren5	51	13	(	(	-LRB-
cord-312340-hpuoren5	51	14	e.g.	e.g.	RB
cord-312340-hpuoren5	51	15	,	,	,
cord-312340-hpuoren5	51	16	heart	heart	NN
cord-312340-hpuoren5	51	17	monitor	monitor	NN
cord-312340-hpuoren5	51	18	patches	patch	NNS
cord-312340-hpuoren5	51	19	,	,	,
cord-312340-hpuoren5	51	20	wearable	wearable	JJ
cord-312340-hpuoren5	51	21	sensors	sensor	NNS
cord-312340-hpuoren5	51	22	)	)	-RRB-
cord-312340-hpuoren5	51	23	.	.	.
cord-312340-hpuoren5	52	1	In	in	IN
cord-312340-hpuoren5	52	2	addition	addition	NN
cord-312340-hpuoren5	52	3	,	,	,
cord-312340-hpuoren5	52	4	as	as	IN
cord-312340-hpuoren5	52	5	recently	recently	RB
cord-312340-hpuoren5	52	6	discussed	discuss	VBN
cord-312340-hpuoren5	52	7	by	by	IN
cord-312340-hpuoren5	52	8	Tan	Tan	NNP
cord-312340-hpuoren5	52	9	et	et	NNP
cord-312340-hpuoren5	52	10	al	al	NNP
cord-312340-hpuoren5	52	11	.	.	NNP
cord-312340-hpuoren5	52	12	,	,	,
cord-312340-hpuoren5	52	13	there	there	EX
cord-312340-hpuoren5	52	14	is	be	VBZ
cord-312340-hpuoren5	52	15	opportunity	opportunity	NN
cord-312340-hpuoren5	52	16	to	to	TO
cord-312340-hpuoren5	52	17	develop	develop	VB
cord-312340-hpuoren5	52	18	a	a	DT
cord-312340-hpuoren5	52	19	decentralized	decentralized	JJ
cord-312340-hpuoren5	52	20	clinical	clinical	JJ
cord-312340-hpuoren5	52	21	trial	trial	NN
cord-312340-hpuoren5	52	22	model	model	NN
cord-312340-hpuoren5	52	23	(	(	-LRB-
cord-312340-hpuoren5	52	24	6	6	CD
cord-312340-hpuoren5	52	25	)	)	-RRB-
cord-312340-hpuoren5	52	26	.	.	.
cord-312340-hpuoren5	53	1	It	-PRON-	PRP
cord-312340-hpuoren5	53	2	should	should	MD
cord-312340-hpuoren5	53	3	also	also	RB
cord-312340-hpuoren5	53	4	be	be	VB
cord-312340-hpuoren5	53	5	noted	note	VBN
cord-312340-hpuoren5	53	6	that	that	IN
cord-312340-hpuoren5	53	7	some	some	DT
cord-312340-hpuoren5	53	8	institutions	institution	NNS
cord-312340-hpuoren5	53	9	have	have	VBP
cord-312340-hpuoren5	53	10	opened	open	VBN
cord-312340-hpuoren5	53	11	COVID-19	covid-19	JJ
cord-312340-hpuoren5	53	12	clinical	clinical	JJ
cord-312340-hpuoren5	53	13	trials	trial	NNS
cord-312340-hpuoren5	53	14	in	in	IN
cord-312340-hpuoren5	53	15	remarkably	remarkably	RB
cord-312340-hpuoren5	53	16	short	short	JJ
cord-312340-hpuoren5	53	17	time	time	NN
cord-312340-hpuoren5	53	18	periods	period	NNS
cord-312340-hpuoren5	53	19	(	(	-LRB-
cord-312340-hpuoren5	53	20	i.e.	i.e.	FW
cord-312340-hpuoren5	53	21	,	,	,
cord-312340-hpuoren5	53	22	in	in	IN
cord-312340-hpuoren5	53	23	a	a	DT
cord-312340-hpuoren5	53	24	matter	matter	NN
cord-312340-hpuoren5	53	25	of	of	IN
cord-312340-hpuoren5	53	26	weeks	week	NNS
cord-312340-hpuoren5	53	27	)	)	-RRB-
cord-312340-hpuoren5	53	28	,	,	,
cord-312340-hpuoren5	53	29	which	which	WDT
cord-312340-hpuoren5	53	30	raises	raise	VBZ
cord-312340-hpuoren5	53	31	the	the	DT
cord-312340-hpuoren5	53	32	question	question	NN
cord-312340-hpuoren5	53	33	as	as	IN
cord-312340-hpuoren5	53	34	to	to	IN
cord-312340-hpuoren5	53	35	why	why	WRB
cord-312340-hpuoren5	53	36	most	most	JJS
cord-312340-hpuoren5	53	37	oncology	oncology	NN
cord-312340-hpuoren5	53	38	trials	trial	NNS
cord-312340-hpuoren5	53	39	take	take	VBP
cord-312340-hpuoren5	53	40	3	3	CD
cord-312340-hpuoren5	53	41	-	-	SYM
cord-312340-hpuoren5	53	42	8	8	CD
cord-312340-hpuoren5	53	43	months	month	NNS
cord-312340-hpuoren5	53	44	to	to	TO
cord-312340-hpuoren5	53	45	open	open	VB
cord-312340-hpuoren5	53	46	at	at	IN
cord-312340-hpuoren5	53	47	academic	academic	JJ
cord-312340-hpuoren5	53	48	centers	center	NNS
cord-312340-hpuoren5	53	49	(	(	-LRB-
cord-312340-hpuoren5	53	50	7	7	CD
cord-312340-hpuoren5	53	51	,	,	,
cord-312340-hpuoren5	53	52	8)	8)	NN
cord-312340-hpuoren5	53	53	.	.	.
cord-312340-hpuoren5	54	1	Protection	protection	NN
cord-312340-hpuoren5	54	2	of	of	IN
cord-312340-hpuoren5	54	3	human	human	JJ
cord-312340-hpuoren5	54	4	subjects	subject	NNS
cord-312340-hpuoren5	54	5	is	be	VBZ
cord-312340-hpuoren5	54	6	always	always	RB
cord-312340-hpuoren5	54	7	of	of	IN
cord-312340-hpuoren5	54	8	paramount	paramount	JJ
cord-312340-hpuoren5	54	9	concern	concern	NN
cord-312340-hpuoren5	54	10	,	,	,
cord-312340-hpuoren5	54	11	however	however	RB
cord-312340-hpuoren5	54	12	it	-PRON-	PRP
cord-312340-hpuoren5	54	13	is	be	VBZ
cord-312340-hpuoren5	54	14	recognized	recognize	VBN
cord-312340-hpuoren5	54	15	that	that	IN
cord-312340-hpuoren5	54	16	many	many	JJ
cord-312340-hpuoren5	54	17	patients	patient	NNS
cord-312340-hpuoren5	54	18	participate	participate	VBP
cord-312340-hpuoren5	54	19	in	in	IN
cord-312340-hpuoren5	54	20	clinical	clinical	JJ
cord-312340-hpuoren5	54	21	trials	trial	NNS
cord-312340-hpuoren5	54	22	because	because	IN
cord-312340-hpuoren5	54	23	the	the	DT
cord-312340-hpuoren5	54	24	studies	study	NNS
cord-312340-hpuoren5	54	25	represent	represent	VBP
cord-312340-hpuoren5	54	26	their	-PRON-	PRP$
cord-312340-hpuoren5	54	27	best	good	JJS
cord-312340-hpuoren5	54	28	therapeutic	therapeutic	JJ
cord-312340-hpuoren5	54	29	option	option	NN
cord-312340-hpuoren5	54	30	.	.	.
cord-312340-hpuoren5	55	1	Furthermore	furthermore	RB
cord-312340-hpuoren5	55	2	,	,	,
cord-312340-hpuoren5	55	3	from	from	IN
cord-312340-hpuoren5	55	4	a	a	DT
cord-312340-hpuoren5	55	5	study	study	NN
cord-312340-hpuoren5	55	6	perspective	perspective	NN
cord-312340-hpuoren5	55	7	,	,	,
cord-312340-hpuoren5	55	8	failing	fail	VBG
cord-312340-hpuoren5	55	9	to	to	TO
cord-312340-hpuoren5	55	10	obtain	obtain	VB
cord-312340-hpuoren5	55	11	pharmacokinetic	pharmacokinetic	JJ
cord-312340-hpuoren5	55	12	data	datum	NNS
cord-312340-hpuoren5	55	13	,	,	,
cord-312340-hpuoren5	55	14	perform	perform	VB
cord-312340-hpuoren5	55	15	correlative	correlative	JJ
cord-312340-hpuoren5	55	16	studies	study	NNS
cord-312340-hpuoren5	55	17	,	,	,
cord-312340-hpuoren5	55	18	electrocardiograms	electrocardiogram	NNS
cord-312340-hpuoren5	55	19	,	,	,
cord-312340-hpuoren5	55	20	or	or	CC
cord-312340-hpuoren5	55	21	imaging	imaging	NN
cord-312340-hpuoren5	55	22	or	or	CC
cord-312340-hpuoren5	55	23	biopsies	biopsy	NNS
cord-312340-hpuoren5	55	24	to	to	TO
cord-312340-hpuoren5	55	25	document	document	VB
cord-312340-hpuoren5	55	26	disease	disease	NN
cord-312340-hpuoren5	55	27	response	response	NN
cord-312340-hpuoren5	55	28	could	could	MD
cord-312340-hpuoren5	55	29	result	result	VB
cord-312340-hpuoren5	55	30	in	in	IN
cord-312340-hpuoren5	55	31	inaccurate	inaccurate	JJ
cord-312340-hpuoren5	55	32	conclusions	conclusion	NNS
cord-312340-hpuoren5	55	33	about	about	IN
cord-312340-hpuoren5	55	34	a	a	DT
cord-312340-hpuoren5	55	35	novel	novel	JJ
cord-312340-hpuoren5	55	36	therapy	therapy	NN
cord-312340-hpuoren5	55	37	's	's	POS
cord-312340-hpuoren5	55	38	safety	safety	NN
cord-312340-hpuoren5	55	39	profile	profile	NN
cord-312340-hpuoren5	55	40	,	,	,
cord-312340-hpuoren5	55	41	optimal	optimal	JJ
cord-312340-hpuoren5	55	42	dosing	dosing	NN
cord-312340-hpuoren5	55	43	and/or	and/or	CC
cord-312340-hpuoren5	55	44	efficacy	efficacy	NN
cord-312340-hpuoren5	55	45	.	.	.
cord-312340-hpuoren5	56	1	As	as	IN
cord-312340-hpuoren5	56	2	noted	note	VBN
cord-312340-hpuoren5	56	3	by	by	IN
cord-312340-hpuoren5	56	4	Saini	Saini	NNP
cord-312340-hpuoren5	56	5	et	et	NNP
cord-312340-hpuoren5	56	6	al	al	NNP
cord-312340-hpuoren5	56	7	.	.	.
cord-312340-hpuoren5	57	1	,	,	,
cord-312340-hpuoren5	57	2	the	the	DT
cord-312340-hpuoren5	57	3	long	long	JJ
cord-312340-hpuoren5	57	4	-	-	HYPH
cord-312340-hpuoren5	57	5	term	term	NN
cord-312340-hpuoren5	57	6	consequences	consequence	NNS
cord-312340-hpuoren5	57	7	of	of	IN
cord-312340-hpuoren5	57	8	decreased	decrease	VBN
cord-312340-hpuoren5	57	9	trial	trial	NN
cord-312340-hpuoren5	57	10	accruals	accrual	NNS
cord-312340-hpuoren5	57	11	will	will	MD
cord-312340-hpuoren5	57	12	affect	affect	VB
cord-312340-hpuoren5	57	13	drug	drug	NN
cord-312340-hpuoren5	57	14	development	development	NN
cord-312340-hpuoren5	57	15	timelines	timeline	NNS
cord-312340-hpuoren5	57	16	and	and	CC
cord-312340-hpuoren5	57	17	ultimately	ultimately	RB
cord-312340-hpuoren5	57	18	delay	delay	VBP
cord-312340-hpuoren5	57	19	getting	get	VBG
cord-312340-hpuoren5	57	20	promising	promising	JJ
cord-312340-hpuoren5	57	21	treatments	treatment	NNS
cord-312340-hpuoren5	57	22	to	to	IN
cord-312340-hpuoren5	57	23	patients	patient	NNS
cord-312340-hpuoren5	57	24	(	(	-LRB-
cord-312340-hpuoren5	57	25	9	9	CD
cord-312340-hpuoren5	57	26	)	)	-RRB-
cord-312340-hpuoren5	57	27	.	.	.
cord-312340-hpuoren5	58	1	In	in	IN
cord-312340-hpuoren5	58	2	this	this	DT
cord-312340-hpuoren5	58	3	country	country	NN
cord-312340-hpuoren5	58	4	,	,	,
cord-312340-hpuoren5	58	5	the	the	DT
cord-312340-hpuoren5	58	6	actions	action	NNS
cord-312340-hpuoren5	58	7	of	of	IN
cord-312340-hpuoren5	58	8	a	a	DT
cord-312340-hpuoren5	58	9	few	few	JJ
cord-312340-hpuoren5	58	10	(	(	-LRB-
cord-312340-hpuoren5	58	11	i.e.	i.e.	FW
cord-312340-hpuoren5	58	12	,	,	,
cord-312340-hpuoren5	58	13	those	those	DT
cord-312340-hpuoren5	58	14	who	who	WP
cord-312340-hpuoren5	58	15	participate	participate	VBP
cord-312340-hpuoren5	58	16	in	in	IN
cord-312340-hpuoren5	58	17	clinical	clinical	JJ
cord-312340-hpuoren5	58	18	trials	trial	NNS
cord-312340-hpuoren5	58	19	)	)	-RRB-
cord-312340-hpuoren5	58	20	affect	affect	VBP
cord-312340-hpuoren5	58	21	the	the	DT
cord-312340-hpuoren5	58	22	outcomes	outcome	NNS
cord-312340-hpuoren5	58	23	of	of	IN
cord-312340-hpuoren5	58	24	the	the	DT
cord-312340-hpuoren5	58	25	many	many	JJ
cord-312340-hpuoren5	58	26	(	(	-LRB-
cord-312340-hpuoren5	58	27	i.e.	i.e.	FW
cord-312340-hpuoren5	58	28	,	,	,
cord-312340-hpuoren5	58	29	the	the	DT
cord-312340-hpuoren5	58	30	general	general	JJ
cord-312340-hpuoren5	58	31	oncology	oncology	NN
cord-312340-hpuoren5	58	32	population	population	NNP
cord-312340-hpuoren5	58	33	)	)	-RRB-
cord-312340-hpuoren5	58	34	who	who	WP
cord-312340-hpuoren5	58	35	benefit	benefit	VBP
cord-312340-hpuoren5	58	36	from	from	IN
cord-312340-hpuoren5	58	37	the	the	DT
cord-312340-hpuoren5	58	38	approval	approval	NN
cord-312340-hpuoren5	58	39	of	of	IN
cord-312340-hpuoren5	58	40	new	new	JJ
cord-312340-hpuoren5	58	41	drugs	drug	NNS
cord-312340-hpuoren5	58	42	and	and	CC
cord-312340-hpuoren5	58	43	therapies	therapy	NNS
cord-312340-hpuoren5	58	44	.	.	.
cord-312340-hpuoren5	59	1	The	the	DT
cord-312340-hpuoren5	59	2	risk	risk	NN
cord-312340-hpuoren5	59	3	that	that	IN
cord-312340-hpuoren5	59	4	COVID-19	COVID-19	,
cord-312340-hpuoren5	59	5	poses	pose	NNS
cord-312340-hpuoren5	59	6	for	for	IN
cord-312340-hpuoren5	59	7	oncology	oncology	NN
cord-312340-hpuoren5	59	8	patients	patient	NNS
cord-312340-hpuoren5	59	9	can	can	MD
cord-312340-hpuoren5	59	10	not	not	RB
cord-312340-hpuoren5	59	11	be	be	VB
cord-312340-hpuoren5	59	12	underestimated	underestimate	VBN
cord-312340-hpuoren5	60	1	and	and	CC
cord-312340-hpuoren5	60	2	it	-PRON-	PRP
cord-312340-hpuoren5	60	3	is	be	VBZ
cord-312340-hpuoren5	60	4	critical	critical	JJ
cord-312340-hpuoren5	60	5	that	that	IN
cord-312340-hpuoren5	60	6	the	the	DT
cord-312340-hpuoren5	60	7	field	field	NN
cord-312340-hpuoren5	60	8	gather	gather	VBP
cord-312340-hpuoren5	60	9	as	as	RB
cord-312340-hpuoren5	60	10	much	much	JJ
cord-312340-hpuoren5	60	11	information	information	NN
cord-312340-hpuoren5	60	12	as	as	IN
cord-312340-hpuoren5	60	13	possible	possible	JJ
cord-312340-hpuoren5	60	14	to	to	TO
cord-312340-hpuoren5	60	15	guide	guide	VB
cord-312340-hpuoren5	60	16	us	-PRON-	PRP
cord-312340-hpuoren5	60	17	in	in	IN
cord-312340-hpuoren5	60	18	making	make	VBG
cord-312340-hpuoren5	60	19	treatment	treatment	NN
cord-312340-hpuoren5	60	20	decisions	decision	NNS
cord-312340-hpuoren5	60	21	.	.	.
cord-312340-hpuoren5	61	1	To	to	IN
cord-312340-hpuoren5	61	2	this	this	DT
cord-312340-hpuoren5	61	3	end	end	NN
cord-312340-hpuoren5	61	4	,	,	,
cord-312340-hpuoren5	61	5	there	there	EX
cord-312340-hpuoren5	61	6	are	be	VBP
cord-312340-hpuoren5	61	7	many	many	JJ
cord-312340-hpuoren5	61	8	groups	group	NNS
cord-312340-hpuoren5	61	9	,	,	,
cord-312340-hpuoren5	61	10	including	include	VBG
cord-312340-hpuoren5	61	11	ASCO	ASCO	NNP
cord-312340-hpuoren5	61	12	and	and	CC
cord-312340-hpuoren5	61	13	the	the	DT
cord-312340-hpuoren5	61	14	American	American	NNP
cord-312340-hpuoren5	61	15	Society	Society	NNP
cord-312340-hpuoren5	61	16	of	of	IN
cord-312340-hpuoren5	61	17	Hematology	Hematology	NNP
cord-312340-hpuoren5	61	18	,	,	,
cord-312340-hpuoren5	61	19	that	that	WDT
cord-312340-hpuoren5	61	20	have	have	VBP
cord-312340-hpuoren5	61	21	created	create	VBN
cord-312340-hpuoren5	61	22	registries	registry	NNS
cord-312340-hpuoren5	61	23	in	in	IN
cord-312340-hpuoren5	61	24	order	order	NN
cord-312340-hpuoren5	61	25	to	to	TO
cord-312340-hpuoren5	61	26	collect	collect	VB
cord-312340-hpuoren5	61	27	data	datum	NNS
cord-312340-hpuoren5	61	28	on	on	IN
cord-312340-hpuoren5	61	29	outcomes	outcome	NNS
cord-312340-hpuoren5	61	30	of	of	IN
cord-312340-hpuoren5	61	31	oncology	oncology	NN
cord-312340-hpuoren5	61	32	patients	patient	NNS
cord-312340-hpuoren5	61	33	infected	infect	VBN
cord-312340-hpuoren5	61	34	with	with	IN
cord-312340-hpuoren5	61	35	SARS	SARS	NNP
cord-312340-hpuoren5	61	36	-	-	HYPH
cord-312340-hpuoren5	61	37	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	61	38	.	.	.
cord-312340-hpuoren5	62	1	The	the	DT
cord-312340-hpuoren5	62	2	impact	impact	NN
cord-312340-hpuoren5	62	3	of	of	IN
cord-312340-hpuoren5	62	4	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	62	5	on	on	IN
cord-312340-hpuoren5	62	6	the	the	DT
cord-312340-hpuoren5	62	7	immune	immune	JJ
cord-312340-hpuoren5	62	8	system	system	NN
cord-312340-hpuoren5	62	9	,	,	,
cord-312340-hpuoren5	62	10	even	even	RB
cord-312340-hpuoren5	62	11	in	in	IN
cord-312340-hpuoren5	62	12	immunocompetent	immunocompetent	JJ
cord-312340-hpuoren5	62	13	patients	patient	NNS
cord-312340-hpuoren5	62	14	is	be	VBZ
cord-312340-hpuoren5	62	15	striking	striking	JJ
cord-312340-hpuoren5	62	16	,	,	,
cord-312340-hpuoren5	62	17	and	and	CC
cord-312340-hpuoren5	62	18	is	be	VBZ
cord-312340-hpuoren5	62	19	somewhat	somewhat	RB
cord-312340-hpuoren5	62	20	reminiscent	reminiscent	JJ
cord-312340-hpuoren5	62	21	of	of	IN
cord-312340-hpuoren5	62	22	the	the	DT
cord-312340-hpuoren5	62	23	cytokine	cytokine	NN
cord-312340-hpuoren5	62	24	release	release	NN
cord-312340-hpuoren5	62	25	syndrome	syndrome	NN
cord-312340-hpuoren5	62	26	associated	associate	VBN
cord-312340-hpuoren5	62	27	with	with	IN
cord-312340-hpuoren5	62	28	CAR	CAR	NNP
cord-312340-hpuoren5	62	29	T	t	NN
cord-312340-hpuoren5	62	30	-	-	HYPH
cord-312340-hpuoren5	62	31	cell	cell	NN
cord-312340-hpuoren5	62	32	therapy	therapy	NN
cord-312340-hpuoren5	62	33	(	(	-LRB-
cord-312340-hpuoren5	62	34	10	10	CD
cord-312340-hpuoren5	62	35	)	)	-RRB-
cord-312340-hpuoren5	62	36	.	.	.
cord-312340-hpuoren5	63	1	The	the	DT
cord-312340-hpuoren5	63	2	degree	degree	NN
cord-312340-hpuoren5	63	3	to	to	TO
cord-312340-hpuoren5	63	4	which	which	WDT
cord-312340-hpuoren5	63	5	oncology	oncology	NN
cord-312340-hpuoren5	63	6	patients	patient	NNS
cord-312340-hpuoren5	63	7	have	have	VBP
cord-312340-hpuoren5	63	8	impaired	impair	VBN
cord-312340-hpuoren5	63	9	immune	immune	JJ
cord-312340-hpuoren5	63	10	responses	response	NNS
cord-312340-hpuoren5	63	11	varies	vary	VBZ
cord-312340-hpuoren5	63	12	widely	widely	RB
cord-312340-hpuoren5	63	13	depending	depend	VBG
cord-312340-hpuoren5	63	14	on	on	IN
cord-312340-hpuoren5	63	15	the	the	DT
cord-312340-hpuoren5	63	16	specific	specific	JJ
cord-312340-hpuoren5	63	17	malignancy	malignancy	NN
cord-312340-hpuoren5	63	18	type	type	NN
cord-312340-hpuoren5	63	19	and	and	CC
cord-312340-hpuoren5	63	20	therapy	therapy	NN
cord-312340-hpuoren5	63	21	.	.	.
cord-312340-hpuoren5	64	1	It	-PRON-	PRP
cord-312340-hpuoren5	64	2	is	be	VBZ
cord-312340-hpuoren5	64	3	difficult	difficult	JJ
cord-312340-hpuoren5	64	4	to	to	TO
cord-312340-hpuoren5	64	5	predict	predict	VB
cord-312340-hpuoren5	64	6	what	what	WP
cord-312340-hpuoren5	64	7	the	the	DT
cord-312340-hpuoren5	64	8	impact	impact	NN
cord-312340-hpuoren5	64	9	of	of	IN
cord-312340-hpuoren5	64	10	various	various	JJ
cord-312340-hpuoren5	64	11	immunotherapeutic	immunotherapeutic	JJ
cord-312340-hpuoren5	64	12	modalities	modality	NNS
cord-312340-hpuoren5	64	13	such	such	JJ
cord-312340-hpuoren5	64	14	as	as	IN
cord-312340-hpuoren5	64	15	CAR	CAR	NNP
cord-312340-hpuoren5	64	16	T	T	NNP
cord-312340-hpuoren5	64	17	-	-	HYPH
cord-312340-hpuoren5	64	18	cells	cell	NNS
cord-312340-hpuoren5	64	19	,	,	,
cord-312340-hpuoren5	64	20	immunomodulatory	immunomodulatory	JJ
cord-312340-hpuoren5	64	21	agents	agent	NNS
cord-312340-hpuoren5	64	22	and	and	CC
cord-312340-hpuoren5	64	23	immune	immune	JJ
cord-312340-hpuoren5	64	24	checkpoint	checkpoint	NN
cord-312340-hpuoren5	64	25	inhibitors	inhibitor	NNS
cord-312340-hpuoren5	64	26	will	will	MD
cord-312340-hpuoren5	64	27	have	have	VB
cord-312340-hpuoren5	64	28	on	on	IN
cord-312340-hpuoren5	64	29	COVID-19	covid-19	JJ
cord-312340-hpuoren5	64	30	severity	severity	NN
cord-312340-hpuoren5	64	31	.	.	.
cord-312340-hpuoren5	65	1	It	-PRON-	PRP
cord-312340-hpuoren5	65	2	is	be	VBZ
cord-312340-hpuoren5	65	3	imperative	imperative	JJ
cord-312340-hpuoren5	65	4	that	that	IN
cord-312340-hpuoren5	65	5	comprehensive	comprehensive	JJ
cord-312340-hpuoren5	65	6	immune	immune	JJ
cord-312340-hpuoren5	65	7	profiling	profiling	NN
cord-312340-hpuoren5	65	8	studies	study	NNS
cord-312340-hpuoren5	65	9	be	be	VB
cord-312340-hpuoren5	65	10	performed	perform	VBN
cord-312340-hpuoren5	65	11	to	to	TO
cord-312340-hpuoren5	65	12	evaluate	evaluate	VB
cord-312340-hpuoren5	65	13	the	the	DT
cord-312340-hpuoren5	65	14	immune	immune	JJ
cord-312340-hpuoren5	65	15	responses	response	NNS
cord-312340-hpuoren5	65	16	in	in	IN
cord-312340-hpuoren5	65	17	these	these	DT
cord-312340-hpuoren5	65	18	patient	patient	JJ
cord-312340-hpuoren5	65	19	populations	population	NNS
cord-312340-hpuoren5	65	20	and	and	CC
cord-312340-hpuoren5	65	21	that	that	IN
cord-312340-hpuoren5	65	22	oncology	oncology	NN
cord-312340-hpuoren5	65	23	patients	patient	NNS
cord-312340-hpuoren5	65	24	be	be	VB
cord-312340-hpuoren5	65	25	included	include	VBN
cord-312340-hpuoren5	65	26	in	in	IN
cord-312340-hpuoren5	65	27	COVID-19	covid-19	JJ
cord-312340-hpuoren5	65	28	clinical	clinical	JJ
cord-312340-hpuoren5	65	29	trials	trial	NNS
cord-312340-hpuoren5	65	30	.	.	.
cord-312340-hpuoren5	66	1	As	as	IN
cord-312340-hpuoren5	66	2	COVID-19	covid-19	JJ
cord-312340-hpuoren5	66	3	testing	testing	NN
cord-312340-hpuoren5	66	4	(	(	-LRB-
cord-312340-hpuoren5	66	5	both	both	DT
cord-312340-hpuoren5	66	6	for	for	IN
cord-312340-hpuoren5	66	7	viral	viral	JJ
cord-312340-hpuoren5	66	8	RNA	RNA	NNP
cord-312340-hpuoren5	66	9	and	and	CC
cord-312340-hpuoren5	66	10	serology	serology	NN
cord-312340-hpuoren5	66	11	)	)	-RRB-
cord-312340-hpuoren5	66	12	become	become	VBP
cord-312340-hpuoren5	66	13	more	more	RBR
cord-312340-hpuoren5	66	14	readily	readily	RB
cord-312340-hpuoren5	66	15	available	available	JJ
cord-312340-hpuoren5	66	16	,	,	,
cord-312340-hpuoren5	66	17	there	there	EX
cord-312340-hpuoren5	66	18	is	be	VBZ
cord-312340-hpuoren5	66	19	an	an	DT
cord-312340-hpuoren5	66	20	opportunity	opportunity	NN
cord-312340-hpuoren5	66	21	to	to	TO
cord-312340-hpuoren5	66	22	begin	begin	VB
cord-312340-hpuoren5	66	23	rigorously	rigorously	RB
cord-312340-hpuoren5	66	24	assessing	assess	VBG
cord-312340-hpuoren5	66	25	SARS	SARS	NNP
cord-312340-hpuoren5	66	26	-	-	HYPH
cord-312340-hpuoren5	66	27	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	66	28	status	status	NN
cord-312340-hpuoren5	66	29	prior	prior	RB
cord-312340-hpuoren5	66	30	to	to	IN
cord-312340-hpuoren5	66	31	initiation	initiation	NN
cord-312340-hpuoren5	66	32	of	of	IN
cord-312340-hpuoren5	66	33	high	high	JJ
cord-312340-hpuoren5	66	34	-	-	HYPH
cord-312340-hpuoren5	66	35	risk	risk	NN
cord-312340-hpuoren5	66	36	therapies	therapy	NNS
cord-312340-hpuoren5	66	37	.	.	.
cord-312340-hpuoren5	67	1	Finally	finally	RB
cord-312340-hpuoren5	67	2	,	,	,
cord-312340-hpuoren5	67	3	there	there	EX
cord-312340-hpuoren5	67	4	is	be	VBZ
cord-312340-hpuoren5	67	5	also	also	RB
cord-312340-hpuoren5	67	6	significant	significant	JJ
cord-312340-hpuoren5	67	7	Accepted	Accepted	NNP
cord-312340-hpuoren5	67	8	Article	Article	NNP
cord-312340-hpuoren5	67	9	opportunity	opportunity	NN
cord-312340-hpuoren5	67	10	to	to	TO
cord-312340-hpuoren5	67	11	utilize	utilize	VB
cord-312340-hpuoren5	67	12	clinical	clinical	JJ
cord-312340-hpuoren5	67	13	pharmacology	pharmacology	NN
cord-312340-hpuoren5	67	14	principles	principle	NNS
cord-312340-hpuoren5	67	15	and	and	CC
cord-312340-hpuoren5	67	16	prospectively	prospectively	RB
cord-312340-hpuoren5	67	17	evaluate	evaluate	VB
cord-312340-hpuoren5	67	18	the	the	DT
cord-312340-hpuoren5	67	19	impact	impact	NN
cord-312340-hpuoren5	67	20	of	of	IN
cord-312340-hpuoren5	67	21	adjustments	adjustment	NNS
cord-312340-hpuoren5	67	22	in	in	IN
cord-312340-hpuoren5	67	23	dosing	dosing	NN
cord-312340-hpuoren5	67	24	of	of	IN
cord-312340-hpuoren5	67	25	chemotherapy	chemotherapy	NN
cord-312340-hpuoren5	67	26	during	during	IN
cord-312340-hpuoren5	67	27	the	the	DT
cord-312340-hpuoren5	67	28	pandemic	pandemic	NN
cord-312340-hpuoren5	67	29	.	.	.
cord-312340-hpuoren5	68	1	It	-PRON-	PRP
cord-312340-hpuoren5	68	2	has	have	VBZ
cord-312340-hpuoren5	68	3	been	be	VBN
cord-312340-hpuoren5	68	4	said	say	VBN
cord-312340-hpuoren5	68	5	that	that	IN
cord-312340-hpuoren5	68	6	we	-PRON-	PRP
cord-312340-hpuoren5	68	7	should	should	MD
cord-312340-hpuoren5	68	8	view	view	VB
cord-312340-hpuoren5	68	9	the	the	DT
cord-312340-hpuoren5	68	10	pandemic	pandemic	NN
cord-312340-hpuoren5	68	11	as	as	IN
cord-312340-hpuoren5	68	12	a	a	DT
cord-312340-hpuoren5	68	13	marathon	marathon	NN
cord-312340-hpuoren5	68	14	and	and	CC
cord-312340-hpuoren5	68	15	not	not	RB
cord-312340-hpuoren5	68	16	a	a	DT
cord-312340-hpuoren5	68	17	sprint	sprint	NN
cord-312340-hpuoren5	68	18	,	,	,
cord-312340-hpuoren5	68	19	but	but	CC
cord-312340-hpuoren5	68	20	the	the	DT
cord-312340-hpuoren5	68	21	reality	reality	NN
cord-312340-hpuoren5	68	22	is	be	VBZ
cord-312340-hpuoren5	68	23	that	that	IN
cord-312340-hpuoren5	68	24	even	even	RB
cord-312340-hpuoren5	68	25	marathons	marathon	NNS
cord-312340-hpuoren5	68	26	have	have	VBP
cord-312340-hpuoren5	68	27	a	a	DT
cord-312340-hpuoren5	68	28	finish	finish	NN
cord-312340-hpuoren5	68	29	line	line	NN
cord-312340-hpuoren5	68	30	.	.	.
cord-312340-hpuoren5	69	1	In	in	IN
cord-312340-hpuoren5	69	2	contrast	contrast	NN
cord-312340-hpuoren5	69	3	,	,	,
cord-312340-hpuoren5	69	4	there	there	EX
cord-312340-hpuoren5	69	5	may	may	MD
cord-312340-hpuoren5	69	6	not	not	RB
cord-312340-hpuoren5	69	7	be	be	VB
cord-312340-hpuoren5	69	8	an	an	DT
cord-312340-hpuoren5	69	9	end	end	NN
cord-312340-hpuoren5	69	10	in	in	IN
cord-312340-hpuoren5	69	11	sight	sight	NN
cord-312340-hpuoren5	69	12	for	for	IN
cord-312340-hpuoren5	69	13	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	69	14	and	and	CC
cord-312340-hpuoren5	69	15	patients	patient	NNS
cord-312340-hpuoren5	69	16	with	with	IN
cord-312340-hpuoren5	69	17	malignancies	malignancy	NNS
cord-312340-hpuoren5	69	18	.	.	.
cord-312340-hpuoren5	70	1	Even	even	RB
cord-312340-hpuoren5	70	2	if	if	IN
cord-312340-hpuoren5	70	3	an	an	DT
cord-312340-hpuoren5	70	4	effective	effective	JJ
cord-312340-hpuoren5	70	5	vaccine	vaccine	NN
cord-312340-hpuoren5	70	6	is	be	VBZ
cord-312340-hpuoren5	70	7	identified	identify	VBN
cord-312340-hpuoren5	70	8	,	,	,
cord-312340-hpuoren5	70	9	it	-PRON-	PRP
cord-312340-hpuoren5	70	10	is	be	VBZ
cord-312340-hpuoren5	70	11	likely	likely	JJ
cord-312340-hpuoren5	70	12	that	that	IN
cord-312340-hpuoren5	70	13	the	the	DT
cord-312340-hpuoren5	70	14	virus	virus	NN
cord-312340-hpuoren5	70	15	will	will	MD
cord-312340-hpuoren5	70	16	not	not	RB
cord-312340-hpuoren5	70	17	be	be	VB
cord-312340-hpuoren5	70	18	eradicated	eradicate	VBN
cord-312340-hpuoren5	70	19	,	,	,
cord-312340-hpuoren5	70	20	given	give	VBN
cord-312340-hpuoren5	70	21	the	the	DT
cord-312340-hpuoren5	70	22	faction	faction	NN
cord-312340-hpuoren5	70	23	of	of	IN
cord-312340-hpuoren5	70	24	society	society	NN
cord-312340-hpuoren5	70	25	who	who	WP
cord-312340-hpuoren5	70	26	will	will	MD
cord-312340-hpuoren5	70	27	refuse	refuse	VB
cord-312340-hpuoren5	70	28	vaccination	vaccination	NN
cord-312340-hpuoren5	70	29	.	.	.
cord-312340-hpuoren5	71	1	Herd	herd	NN
cord-312340-hpuoren5	71	2	immunity	immunity	NN
cord-312340-hpuoren5	71	3	may	may	MD
cord-312340-hpuoren5	71	4	be	be	VB
cord-312340-hpuoren5	71	5	helpful	helpful	JJ
cord-312340-hpuoren5	71	6	to	to	IN
cord-312340-hpuoren5	71	7	some	some	DT
cord-312340-hpuoren5	71	8	extent	extent	NN
cord-312340-hpuoren5	71	9	,	,	,
cord-312340-hpuoren5	71	10	but	but	CC
cord-312340-hpuoren5	71	11	will	will	MD
cord-312340-hpuoren5	71	12	not	not	RB
cord-312340-hpuoren5	71	13	eliminate	eliminate	VB
cord-312340-hpuoren5	71	14	SARS	SARS	NNP
cord-312340-hpuoren5	71	15	-	-	HYPH
cord-312340-hpuoren5	71	16	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	71	17	infections	infection	NNS
cord-312340-hpuoren5	71	18	.	.	.
cord-312340-hpuoren5	72	1	Those	those	DT
cord-312340-hpuoren5	72	2	patients	patient	NNS
cord-312340-hpuoren5	72	3	with	with	IN
cord-312340-hpuoren5	72	4	malignancies	malignancy	NNS
cord-312340-hpuoren5	72	5	,	,	,
cord-312340-hpuoren5	72	6	particularly	particularly	RB
cord-312340-hpuoren5	72	7	those	those	DT
cord-312340-hpuoren5	72	8	with	with	IN
cord-312340-hpuoren5	72	9	a	a	DT
cord-312340-hpuoren5	72	10	diminished	diminished	JJ
cord-312340-hpuoren5	72	11	ability	ability	NN
cord-312340-hpuoren5	72	12	to	to	TO
cord-312340-hpuoren5	72	13	mount	mount	VB
cord-312340-hpuoren5	72	14	antibody	antibody	NN
cord-312340-hpuoren5	72	15	responses	response	NNS
cord-312340-hpuoren5	72	16	,	,	,
cord-312340-hpuoren5	72	17	will	will	MD
cord-312340-hpuoren5	72	18	remain	remain	VB
cord-312340-hpuoren5	72	19	vulnerable	vulnerable	JJ
cord-312340-hpuoren5	72	20	to	to	IN
cord-312340-hpuoren5	72	21	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	72	22	.	.	.
cord-312340-hpuoren5	73	1	The	the	DT
cord-312340-hpuoren5	73	2	mortality	mortality	NN
cord-312340-hpuoren5	73	3	rate	rate	NN
cord-312340-hpuoren5	73	4	due	due	IN
cord-312340-hpuoren5	73	5	to	to	IN
cord-312340-hpuoren5	73	6	SARS	SARS	NNP
cord-312340-hpuoren5	73	7	-	-	HYPH
cord-312340-hpuoren5	73	8	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	73	9	infection	infection	NN
cord-312340-hpuoren5	73	10	may	may	MD
cord-312340-hpuoren5	73	11	be	be	VB
cord-312340-hpuoren5	73	12	relatively	relatively	RB
cord-312340-hpuoren5	73	13	straightforward	straightforward	JJ
cord-312340-hpuoren5	73	14	to	to	TO
cord-312340-hpuoren5	73	15	monitor	monitor	VB
cord-312340-hpuoren5	73	16	.	.	.
cord-312340-hpuoren5	74	1	However	however	RB
cord-312340-hpuoren5	74	2	,	,	,
cord-312340-hpuoren5	74	3	it	-PRON-	PRP
cord-312340-hpuoren5	74	4	will	will	MD
cord-312340-hpuoren5	74	5	be	be	VB
cord-312340-hpuoren5	74	6	much	much	RB
cord-312340-hpuoren5	74	7	more	more	RBR
cord-312340-hpuoren5	74	8	difficult	difficult	JJ
cord-312340-hpuoren5	74	9	to	to	TO
cord-312340-hpuoren5	74	10	estimate	estimate	VB
cord-312340-hpuoren5	74	11	the	the	DT
cord-312340-hpuoren5	74	12	numbers	number	NNS
cord-312340-hpuoren5	74	13	of	of	IN
cord-312340-hpuoren5	74	14	lives	life	NNS
cord-312340-hpuoren5	74	15	lost	lose	VBN
cord-312340-hpuoren5	74	16	or	or	CC
cord-312340-hpuoren5	74	17	shortened	shorten	VBN
cord-312340-hpuoren5	74	18	due	due	IN
cord-312340-hpuoren5	74	19	to	to	IN
cord-312340-hpuoren5	74	20	consequences	consequence	NNS
cord-312340-hpuoren5	74	21	of	of	IN
cord-312340-hpuoren5	74	22	COVID-19	covid-19	NN
cord-312340-hpuoren5	74	23	such	such	JJ
cord-312340-hpuoren5	74	24	as	as	IN
cord-312340-hpuoren5	74	25	:	:	:
cord-312340-hpuoren5	74	26	delays	delay	NNS
cord-312340-hpuoren5	74	27	in	in	IN
cord-312340-hpuoren5	74	28	malignancy	malignancy	NN
cord-312340-hpuoren5	74	29	diagnosis	diagnosis	NN
cord-312340-hpuoren5	74	30	or	or	CC
cord-312340-hpuoren5	74	31	presentation	presentation	NN
cord-312340-hpuoren5	74	32	at	at	IN
cord-312340-hpuoren5	74	33	more	more	RBR
cord-312340-hpuoren5	74	34	advanced	advanced	JJ
cord-312340-hpuoren5	74	35	stages	stage	NNS
cord-312340-hpuoren5	74	36	due	due	IN
cord-312340-hpuoren5	74	37	to	to	IN
cord-312340-hpuoren5	74	38	lack	lack	NN
cord-312340-hpuoren5	74	39	of	of	IN
cord-312340-hpuoren5	74	40	screening	screening	NN
cord-312340-hpuoren5	74	41	or	or	CC
cord-312340-hpuoren5	74	42	access	access	NN
cord-312340-hpuoren5	74	43	to	to	IN
cord-312340-hpuoren5	74	44	primary	primary	JJ
cord-312340-hpuoren5	74	45	care	care	NN
cord-312340-hpuoren5	74	46	,	,	,
cord-312340-hpuoren5	74	47	reduced	reduce	VBN
cord-312340-hpuoren5	74	48	access	access	NN
cord-312340-hpuoren5	74	49	to	to	IN
cord-312340-hpuoren5	74	50	comprehensive	comprehensive	JJ
cord-312340-hpuoren5	74	51	cancer	cancer	NN
cord-312340-hpuoren5	74	52	centers	center	NNS
cord-312340-hpuoren5	74	53	and	and	CC
cord-312340-hpuoren5	74	54	clinical	clinical	JJ
cord-312340-hpuoren5	74	55	trials	trial	NNS
cord-312340-hpuoren5	74	56	,	,	,
cord-312340-hpuoren5	74	57	adjustments	adjustment	NNS
cord-312340-hpuoren5	74	58	made	make	VBN
cord-312340-hpuoren5	74	59	to	to	IN
cord-312340-hpuoren5	74	60	standard	standard	NN
cord-312340-hpuoren5	74	61	of	of	IN
cord-312340-hpuoren5	74	62	care	care	NN
cord-312340-hpuoren5	74	63	chemotherapy	chemotherapy	NN
cord-312340-hpuoren5	74	64	regimens	regimen	NNS
cord-312340-hpuoren5	74	65	that	that	WDT
cord-312340-hpuoren5	74	66	abrogate	abrogate	VBP
cord-312340-hpuoren5	74	67	efficacy	efficacy	NN
cord-312340-hpuoren5	74	68	,	,	,
cord-312340-hpuoren5	74	69	lack	lack	NN
cord-312340-hpuoren5	74	70	of	of	IN
cord-312340-hpuoren5	74	71	insurance	insurance	NN
cord-312340-hpuoren5	74	72	because	because	IN
cord-312340-hpuoren5	74	73	of	of	IN
cord-312340-hpuoren5	74	74	unemployment	unemployment	NN
cord-312340-hpuoren5	74	75	and	and	CC
cord-312340-hpuoren5	74	76	delays	delay	NNS
cord-312340-hpuoren5	74	77	in	in	IN
cord-312340-hpuoren5	74	78	drug	drug	NN
cord-312340-hpuoren5	74	79	development	development	NN
cord-312340-hpuoren5	74	80	.	.	.
cord-312340-hpuoren5	75	1	The	the	DT
cord-312340-hpuoren5	75	2	coming	coming	JJ
cord-312340-hpuoren5	75	3	months	month	NNS
cord-312340-hpuoren5	75	4	to	to	IN
cord-312340-hpuoren5	75	5	years	year	NNS
cord-312340-hpuoren5	75	6	will	will	MD
cord-312340-hpuoren5	75	7	be	be	VB
cord-312340-hpuoren5	75	8	incredibly	incredibly	RB
cord-312340-hpuoren5	75	9	challenging	challenging	JJ
cord-312340-hpuoren5	75	10	,	,	,
cord-312340-hpuoren5	75	11	but	but	CC
cord-312340-hpuoren5	75	12	it	-PRON-	PRP
cord-312340-hpuoren5	75	13	is	be	VBZ
cord-312340-hpuoren5	75	14	paramount	paramount	JJ
cord-312340-hpuoren5	75	15	that	that	IN
cord-312340-hpuoren5	75	16	we	-PRON-	PRP
cord-312340-hpuoren5	75	17	continue	continue	VBP
cord-312340-hpuoren5	75	18	to	to	TO
cord-312340-hpuoren5	75	19	practice	practice	VB
cord-312340-hpuoren5	75	20	evidence	evidence	NN
cord-312340-hpuoren5	75	21	-	-	HYPH
cord-312340-hpuoren5	75	22	based	base	VBN
cord-312340-hpuoren5	75	23	medicine	medicine	NN
cord-312340-hpuoren5	75	24	and	and	CC
cord-312340-hpuoren5	75	25	optimize	optimize	VB
cord-312340-hpuoren5	75	26	the	the	DT
cord-312340-hpuoren5	75	27	conduct	conduct	NN
cord-312340-hpuoren5	75	28	of	of	IN
cord-312340-hpuoren5	75	29	clinical	clinical	JJ
cord-312340-hpuoren5	75	30	trials	trial	NNS
cord-312340-hpuoren5	75	31	in	in	IN
cord-312340-hpuoren5	75	32	order	order	NN
cord-312340-hpuoren5	75	33	to	to	TO
cord-312340-hpuoren5	75	34	mitigate	mitigate	VB
cord-312340-hpuoren5	75	35	the	the	DT
cord-312340-hpuoren5	75	36	risk	risk	NN
cord-312340-hpuoren5	75	37	of	of	IN
cord-312340-hpuoren5	75	38	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	75	39	,	,	,
cord-312340-hpuoren5	75	40	thereby	thereby	RB
cord-312340-hpuoren5	75	41	improving	improve	VBG
cord-312340-hpuoren5	75	42	the	the	DT
cord-312340-hpuoren5	75	43	outcomes	outcome	NNS
cord-312340-hpuoren5	75	44	of	of	IN
cord-312340-hpuoren5	75	45	current	current	JJ
cord-312340-hpuoren5	75	46	and	and	CC
cord-312340-hpuoren5	75	47	future	future	JJ
cord-312340-hpuoren5	75	48	generations	generation	NNS
cord-312340-hpuoren5	75	49	of	of	IN
cord-312340-hpuoren5	75	50	individuals	individual	NNS
cord-312340-hpuoren5	75	51	diagnosed	diagnose	VBN
cord-312340-hpuoren5	75	52	with	with	IN
cord-312340-hpuoren5	75	53	cancer	cancer	NN
cord-312340-hpuoren5	75	54	.	.	.
cord-312340-hpuoren5	75	55	 	 	_SP
cord-312340-hpuoren5	76	1	The	the	DT
cord-312340-hpuoren5	76	2	Role	role	NN
cord-312340-hpuoren5	76	3	of	of	IN
cord-312340-hpuoren5	76	4	Clinical	Clinical	NNP
cord-312340-hpuoren5	76	5	Trial	Trial	NNP
cord-312340-hpuoren5	76	6	Participation	Participation	NNP
cord-312340-hpuoren5	76	7	in	in	IN
cord-312340-hpuoren5	76	8	Cancer	Cancer	NNP
cord-312340-hpuoren5	76	9	Research	Research	NNP
cord-312340-hpuoren5	76	10	:	:	:
cord-312340-hpuoren5	76	11	Barriers	barrier	NNS
cord-312340-hpuoren5	76	12	,	,	,
cord-312340-hpuoren5	76	13	Evidence	evidence	NN
cord-312340-hpuoren5	76	14	,	,	,
cord-312340-hpuoren5	76	15	and	and	CC
cord-312340-hpuoren5	76	16	Strategies	Strategies	NNPS
cord-312340-hpuoren5	76	17	Early	Early	NNP
cord-312340-hpuoren5	76	18	Impact	Impact	NNP
cord-312340-hpuoren5	76	19	of	of	IN
cord-312340-hpuoren5	76	20	COVID-19	COVID-19	NNP
cord-312340-hpuoren5	76	21	on	on	IN
cord-312340-hpuoren5	76	22	the	the	DT
cord-312340-hpuoren5	76	23	Conduct	Conduct	NNP
cord-312340-hpuoren5	76	24	of	of	IN
cord-312340-hpuoren5	76	25	Oncology	Oncology	NNP
cord-312340-hpuoren5	76	26	Clinical	Clinical	NNP
cord-312340-hpuoren5	76	27	Trials	Trials	NNPS
cord-312340-hpuoren5	76	28	and	and	CC
cord-312340-hpuoren5	76	29	Long	Long	NNP
cord-312340-hpuoren5	76	30	-	-	HYPH
cord-312340-hpuoren5	76	31	Term	term	NN
cord-312340-hpuoren5	76	32	Opportunities	Opportunities	NNPS
cord-312340-hpuoren5	76	33	for	for	IN
cord-312340-hpuoren5	76	34	Transformation	transformation	NN
cord-312340-hpuoren5	76	35	:	:	:
cord-312340-hpuoren5	76	36	Findings	finding	NNS
cord-312340-hpuoren5	76	37	From	from	IN
cord-312340-hpuoren5	76	38	an	an	DT
cord-312340-hpuoren5	76	39	Adapting	adapting	NN
cord-312340-hpuoren5	76	40	to	to	IN
cord-312340-hpuoren5	76	41	a	a	DT
cord-312340-hpuoren5	76	42	pandemic	pandemic	NN
cord-312340-hpuoren5	76	43	-conducting	-conducte	VBG
cord-312340-hpuoren5	76	44	oncology	oncology	NN
cord-312340-hpuoren5	76	45	trials	trial	NNS
cord-312340-hpuoren5	76	46	during	during	IN
cord-312340-hpuoren5	76	47	the	the	DT
cord-312340-hpuoren5	76	48	SARS	SARS	NNP
cord-312340-hpuoren5	76	49	-	-	HYPH
cord-312340-hpuoren5	76	50	CoV-2	CoV-2	NNP
cord-312340-hpuoren5	76	51	pandemic	pandemic	NN
cord-312340-hpuoren5	76	52	Time	time	NN
cord-312340-hpuoren5	76	53	to	to	TO
cord-312340-hpuoren5	76	54	activate	activate	VB
cord-312340-hpuoren5	76	55	lung	lung	NN
cord-312340-hpuoren5	76	56	cancer	cancer	NN
cord-312340-hpuoren5	76	57	clinical	clinical	JJ
cord-312340-hpuoren5	76	58	trials	trial	NNS
cord-312340-hpuoren5	76	59	and	and	CC
cord-312340-hpuoren5	76	60	patient	patient	JJ
cord-312340-hpuoren5	76	61	enrollment	enrollment	NN
cord-312340-hpuoren5	76	62	:	:	:
cord-312340-hpuoren5	76	63	a	a	DT
cord-312340-hpuoren5	76	64	representative	representative	JJ
cord-312340-hpuoren5	76	65	comparison	comparison	NN
cord-312340-hpuoren5	76	66	study	study	NN
cord-312340-hpuoren5	76	67	between	between	IN
cord-312340-hpuoren5	76	68	two	two	CD
cord-312340-hpuoren5	76	69	academic	academic	JJ
cord-312340-hpuoren5	76	70	centers	center	NNS
cord-312340-hpuoren5	76	71	across	across	IN
cord-312340-hpuoren5	76	72	the	the	DT
cord-312340-hpuoren5	76	73	atlantic	atlantic	NNP
cord-312340-hpuoren5	76	74	Invisible	Invisible	NNP
cord-312340-hpuoren5	76	75	barriers	barrier	NNS
cord-312340-hpuoren5	76	76	to	to	IN
cord-312340-hpuoren5	76	77	clinical	clinical	JJ
cord-312340-hpuoren5	76	78	trials	trial	NNS
cord-312340-hpuoren5	76	79	:	:	:
cord-312340-hpuoren5	76	80	the	the	DT
cord-312340-hpuoren5	76	81	impact	impact	NN
cord-312340-hpuoren5	76	82	of	of	IN
cord-312340-hpuoren5	76	83	structural	structural	JJ
cord-312340-hpuoren5	76	84	,	,	,
cord-312340-hpuoren5	76	85	infrastructural	infrastructural	JJ
cord-312340-hpuoren5	76	86	,	,	,
cord-312340-hpuoren5	76	87	and	and	CC
cord-312340-hpuoren5	76	88	procedural	procedural	JJ
cord-312340-hpuoren5	76	89	barriers	barrier	NNS
cord-312340-hpuoren5	76	90	to	to	IN
cord-312340-hpuoren5	76	91	opening	open	VBG
cord-312340-hpuoren5	76	92	oncology	oncology	NN
cord-312340-hpuoren5	76	93	clinical	clinical	JJ
cord-312340-hpuoren5	76	94	trials	trial	NNS
cord-312340-hpuoren5	76	95	Effect	Effect	NNP
cord-312340-hpuoren5	76	96	of	of	IN
cord-312340-hpuoren5	76	97	the	the	DT
cord-312340-hpuoren5	76	98	COVID-19	covid-19	JJ
cord-312340-hpuoren5	76	99	pandemic	pandemic	NN
cord-312340-hpuoren5	76	100	on	on	IN
cord-312340-hpuoren5	76	101	cancer	cancer	NN
cord-312340-hpuoren5	76	102	treatment	treatment	NN
cord-312340-hpuoren5	76	103	and	and	CC
cord-312340-hpuoren5	76	104	research	research	NN
cord-312340-hpuoren5	77	1	The	the	DT
cord-312340-hpuoren5	77	2	many	many	JJ
cord-312340-hpuoren5	77	3	faces	face	NNS
cord-312340-hpuoren5	77	4	of	of	IN
cord-312340-hpuoren5	77	5	the	the	DT
cord-312340-hpuoren5	77	6	anti	anti	JJ
cord-312340-hpuoren5	77	7	-	-	JJ
cord-312340-hpuoren5	77	8	COVID	covid	JJ
cord-312340-hpuoren5	77	9	immune	immune	JJ
cord-312340-hpuoren5	77	10	response	response	NN
cord-312340-hpuoren5	77	11	Accepted	accept	VBN
cord-312340-hpuoren5	77	12	Article	Article	NNP